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1 Introduction 
 
1.1 Stimuli-responsive drugs and drug delivery systems – towards 
programmed pharmaceutics 
 
Efforts are currently made to advance traditional drugs or pharmaceuticals to more 
sophisticated and flexible systems. These are able to take into account specific 
environmental conditions in the patient and to respond to them in a desired way. 
Therefore, the drugs themselves or their pharmaceutical formulations are designed 
as programmed “stimuli-responsive” systems (1-3). This trend can be found in all 
areas of drug development and has already achieved success in many cases. The 
intentions thereby are multifarious and aim for example at the reduction of side 
effects and toxicity (on-site activation, ciclesonide/Alvesco® (4)(5)), the generation of 
specific kinetics in drug activation (pH-triggered activation of acid neutralization by 
hydrotalcit (6,7)), the protection of drugs from aggressive environments like gastric 
acid, or – the other way round – the protection of non-target sites in the patient from 
drug effects (enteric-coating of tablets or pellets, Eudragit® (8)), improvements in 
resorption (lipophilized prodrugs Cefuroximaxetil, Oseltamivir (9, 10)), et cetera. This 
concept of programmed stimuli responsiveness, already applied successfully for 
many conventional drugs and therapies, might also be advantageous in the field of 
biotechnological medicines, for instance in gene therapy.  
 
1.2 Gene therapy – gene vectors  
 
Many diseases are based on changes in the genome of the patient. Hence, a causal 
therapy tending not only to eliminate symptoms, but to cure a genetic disease, 
demands an intervention on the gene level. This means that the defective or missing 
gene has to be substituted in the cells of the concerned tissue. Examples for 
diseases that have already been cured with the help of gene therapy are cystic 
fibrososis (11) and severe combined immunodeficiency (SCID) (12, 13). But not only 
inherent genetic diseases can be treated by gene therapy; clinical trials have been 
performed also on the treatment of heart failure, other cardiovascular diseases, 
infectious diseases and more (14). Further, many cancers are susceptive to this kind 
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of treatment. The aim here is to either knock out genes that facilitate tumor growth, 
or to introduce therapeutic genes that – when expressed – antagonize tumor growth 
or cause apoptosis in tumor cells (p53, TNFα) (15-17)(18). Gene therapy could offer 
a chance in cases where tumors are inaccessible to surgical removal, are drug 
resistant or have metastasized. 
In the past, different methods have been developed to insert therapeutic genes into 
patient cells. The applied techniques can be distinguished into two main methods: ex 
vivo therapies, where affected cells are taken from the patient, transfected with the 
new gene outside the body and finally are re-implanted into the patient. In contrast, 
with the aid of gene vectors application of therapeutic genes can also be performed 
in vivo, which means that the therapeutic gene is directly administered to the patient. 
Vectors that are able to recognize their target cells need not be applied 
intratumorally, but can be injected systemically into the bloodstream. The vector then 
reaches its target cells via the circulation and gets internalized mostly by 
endocytosis. After subsequent release from the endosome into the cytoplasm, the 
therapeutic nucleic acid travels to the nucleus, where it has to be taken up; finally the 
transgene can be expressed. Figure 1 shows schematically the steps of a vector 
based transfection process – additionally taking into account the barriers the vector 
has to overcome. 
One possibility for vector mediated gene transfer is the use of viral vectors (19), 
which most commonly implies attenuated adeno- (20) or retroviruses. Thereby the 
viral genome is modified; undesired (i.e. useless, risky) parts are deleted and 
replaced by a therapeutic nucleic acid. The viral particles obtained retain their 
potential to infect cells, but cannot replicate any more. What makes these viral 
vectors so convenient is the fact, that viruses have constantly advanced their 
mechanisms of successfully attacking and infecting their hosts during evolution. 
Consequently, virus derived vectors profiting from this experience, convince by their 
high gene transfer efficiency. Viruses possess for instance mature strategies to 
overcome extra- and intracellular barriers (Figure 1) and to adapt themselves to 
changing conditions in the host, or even to utilize these for their own intentions.  
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Figure 1. Route of a gene vector from the application site to the site of action. 
Extra- and intracellular barriers and hindrances the vector is confronted with: 
(1-2) Increased ionic strength in biological milieu favours aggregation; undesired 
interaction with blood components or non-target cells; inactivation by immune 
system/clearance by RES; degradation of nucleic acids by nucleases;   
? toxicity and/or inactivation of vectors 
(3) Cellular uptake: cell membrane has to be overcome  
(4) Escape into cytosol before recycling to cell surface or acidic/enzymatic 
degradation occur: passage through endosomal membrane; 
(5) Cytosol as diffusion barrier; degradation of nucleic acid by cytosolic nucleases; 
(6) Nuclear envelope has to be passed (in case of nuclear delivery/DNA) 
 
 
For example receptors and other specific structures present on the target cell, are 
exploited for virus-binding and internalization into the cell (adenoviruses/fiber 
proteins (20)). Cytoskeletal structures and organelles in the cytoplasm represent a 
serious hindrance for the diffusion of macromolecules (21, 22) and therefore would 
impair cytoplasmic trafficking from vectors towards the nucleus. Viruses in contrast 
are able to take even advantage of this situation by utilizing the cellular structures 
(microtubules or actin microfilaments) as transport systems (20, 21, 23). Another 
aspect to mention are the sophisticated mechanisms viruses have developed to 
facilitate their release from endosome after cellular uptake by endocytosis (24). This 
includes for example the use of flexible viral structures that are able to respond to 
alterations in the environment by a change in their physicochemical properties. 
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Triggers therefore can be the contact with reductive milieu or a change in pH (22, 
23), occurring for example between the endosomal compartment and extracellular or 
cytoplasmic milieu. Membrane fusiogenic residues for instance become activated 
upon acidification in the endosome (influenza virus: exposure of amphiphilic anionic 
peptide; adenovirus: hydrophobization of penton base protein) and induce 
endosomal release (24). These and further mechanisms make viruses so efficient in 
infecting and transfecting cells. However, the application of viral particles into a 
patient implicates not only advantages, but also holds several risks. Viral proteins 
can cause immunogenic reactions (22, 25), inappropriate insertion of genes into the 
host genome (insertional mutagenesis) can result in oncogenesis or other 
unpredictable diseases (13), and finally there still remains a residual risk that the 
altered virus regains its ability to generate infectious viral particles which cause 
diseases (26). 
The alternative to viruses are non-viral delivery systems. This includes naked 
plasmid DNA (pDNA), as well as lipoplexes (composed of nucleic acids and cationic 
lipids), polyplexes (nucleic acids compacted by polycations) or combinations of these 
(27, 28). In contrast to naked DNA the use of cationic lipids and polycations has the 
advantage that anionic RNA or DNA macromolecules are compacted by these 
agents, which facilitates efficient cellular uptake and protection of the nucleic acids 
from nucleases. Compared to their viral counterparts non-viral vectors convince 
especially by the ease of synthesis, the lower costs in production, their improved 
immunogenic profile and better compatibility, and their high flexibility concerning the 
size of the transported gene construct (29, 30). However, these preferences are 
confronted with several insufficiencies that have to be compensated. Concerning the 
gene transfer efficiency, most non-viral vectors are still ranking far behind their viral 
counterparts (22). In addition, their toxicity profiles need to be improved further (31, 
32). Thus the utilized polymers are often too large to be excreted (33) and most of 
them can not be degraded, as for example the widely used and efficiently 
transfecting polyethylenimines (PEI). Consequently, they accumulate in the patient´s 
organs and cause toxic side effects. However, substitution of the toxic high 
molecular weight polymers by well compatible small ones does not solve the 
problem, as along with polymer size also their transfection efficiency would get lost 
(29, 34).  
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Furthermore, many non-viral vectors – particularly polyplexes – exhibit a net positive 
surface charge due to the excess of polycation required for high gene transfer 
activity (35). During their circulation in the patient’s blood, these positively charged 
particles can interact with negatively charged physiological compounds which results 
in significant toxicity and/or poor efficiency, due to binding to plasma proteins or 
blood cells, aggregation and complement activation (36, 37). Surface neutralization 
by PEGylation, i.e. the modification with the hydrophilic polymer poly(ethylene glycol) 
(PEG) prevents polyplexes from these undesired interactions as well as from rapid 
elimination by the reticuloendothelial system (RES) and thus decreases toxicity and 
extends circulation time (38). However, covering the polyplex surface with neutral 
polymers not only reduces undesired interactions, but also the desired binding to the 
negatively charged cell membrane of the target cells (39). Following the viral 
concept, the resulting reduced association and polyplex uptake into the cell can be 
overcome by the attachment of a targeting ligand to the polyplex for receptor-
mediated uptake. PEI polyplexes containing PEG and cell-targeting ligands have 
been successfully applied in vitro and in vivo (38-44). While the uptake problem of 
PEG shielded particles can be solved satisfactorily, there still remain difficulties 
concerning the intracellular fate of PEGylated polyplexes. Extensive PEGylation, 
though being beneficial for systemic circulation, appears to negatively affect 
endosomal release of the delivered nucleic acid and leads to a remarkable reduction 
of transfection efficiency.  
Thus, at the first view, it appears somehow contradictory to combine high 
transfection efficiency and low toxicity in just one vector. Indeed, non-viral vectors 
even when equipped with virus-like attributes like ligands are still not able to meet all 
the different requirements needed for successful transfection. What still distinguishes 
them from the flexible viruses is their static nature. Thus, if one would design non-
viral vectors able to change their characteristics depending on the respective 
demands – i.e., to make them stimuli responsive like viruses – this inconsistency 
might be resolved. 
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1.3 Mimicking viruses` flexibility: pH-responsive non-viral gene 
vectors 
 
Learning from nature – in particular from viruses – is the device for the design of 
more flexible, stimuli responsive and efficient non-viral gene delivery systems (45, 
46). The ingenious mechanisms that viruses have developed (23) to overcome the 
barriers they are confronted with in their host (Figure 1) (32), can serve as guide 
towards the creation of improved non-viral vectors.  
A polymer type equipped intrinsically with a virus like feature is for example 
polyethylenimine (i.e. PEI22K, PEI25K). High m.w. polyethylenimines mediate gene 
transfer very effectively. The special characteristic of these polycations is their 
particularly high density of protonable amines (30, 47), which act as stimuli 
responsive elements mediating endosomal release: when polyplexes are trapped in 
an endosome and the endosome matures to an endolysosome, the pH starts to 
drop. Upon this drop in pH PEI becomes further protonated. The increased positive 
polymer charge facilitates membrane interactions (22, 32, 48) and causes osmotic 
effects, leading to endosomal swelling and finally endosomal rupture (proton sponge 
hypothesis) (22, 32, 49). In this way PEI provokes the release of the vector into the 
cytoplasm before degradation in the endolysosome begins. This property of PEI 
reminds strongly of a viral attribute, as viruses also possess mechanisms for 
endosomal escape initiated by the acidification of the endosomal milieu (22, 24). 
Nevertheless, PEI though often used as golden standard for non-viral transfections, 
still is not the perfect polymer. Inclusion of other stimuli triggered characteristics will 
be necessary to further improve vector characteristics and will be discussed below. 
 
1.3.1 Acid-labile PEG shielding of gene vectors  
As PEGylation improves polyplex characteristics in the extracellular compartment, 
but is impedimental for the following intracellular steps in the transfection process, it 
is obvious to think about methods of introducing PEG to polyplexes reversibly. Thus, 
when the PEG shield has become useless after cellular uptake of the polyplex, it will 
be deleted again. The cleavage of the linkage between the PEG and the polycation 
has to occur upon a specific stimulus present only in the endosome but not in the 
extracellular environment, to assure that polyplex deshielding does not occur before 
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endocytosis.  Further, this cleavage has to take place fast enough to allow the 
subsequent endosomal release before transformation of the endosome into a 
lysosome, which would result in vector degradation. Following many viruses which 
use the pH drop occurring in the endosome as a trigger for their uncoating (23), non-
viral vectors could also exploit this change in pH as stimulus for their deshielding.   
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Figure 2. Schematic illustration of the concept of acid-sensitive PEGylation of 
polyplexes 
(A) Assembly of the vector out of nucleic acid and reversibly PEGylated polycation 
(B) Systemic application of the gene vector to the patient; PEG shielding, stable in 
extracellular environment (physiologic pH of 7.4), prevents undesired interactions 
during circulation in the blood stream 
(C) Upon endocytosis and endosomal acidification acid-labile linkages between PEG 
and polycation are cleaved and cause polyplex deshielding; recovery of positive 
surface charge facilitates polyplex release from endosome; 
 
This implies that the PEG molecules have to be coupled to the vector via a pH-
sensitive bond. Linker molecules that show an appropriate pH-sensitivity towards 
slight decreases in pH, such as the decrease from physiologic pH of 7.4  to 
endosomal pHs of about 6-5, can be found among hydrazones (50), vinyl ethers 
(51), orthoesters (52-54) and acetals (55-57). Lipoplexes and polyplexes equipped 
with such a pH-sensitive PEG shield have already been found to mediate enhanced 
gene transfer efficiency (50, 52, 53). Reversible shielding of PEI polyplexes for 
instance was achieved in an indirect manner by the conjugation of PEG to polylysine 
via a hydrazone bond (50). Unfortunately the chemistry was not applicable for direct 
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conjugation of PEG to PEI because of insufficient stability of the resulting PEI 
conjugate. Nevertheless, these data confirm that the concept of reversible 
PEGylation indeed is promising. 
 
1.3.2 pH-sensitive degradable cationic carriers 
PEGylation allows reducing toxicity of existing, prefabricated polycations like PEI or 
PLL retrospectively. Alternatively, if one does not rely on the commercial polymers, 
the aspect of an improved toxicity profile can already be considered when 
developing new polymer synthesis. Here, a particular interesting aspect is the design 
of polymers that can undergo biodegradation. 
As mentioned above, high transfection efficiency is almost always associated with 
high vector toxicity (31, 58). For example polyethylenimines (PEI), macromolecular 
polycations of molecular weights around 22-25 kDa, mediate gene transfer very 
effectively but cause considerable toxic effects (31). Toxicity of PEIs is, among other 
things, based on the fact that these polymers are not degradable into small 
excretable degradation products. In contrast, shorter polyethylenimines such as 800 
Da OEI possess just negligible toxicity, but exhibit only very poor gene transfer 
capacity. Therefore, one approach towards safer vectors is to design biodegradable 
polycations of adequate sizes, which allow gene transfer as effective as their stable 
PEI counterparts, but with time or upon a specific stimulus, decompose into non-
toxic small degradation products. Several groups already have been working on this 
approach by inserting diverse degradable functions into their polymers. These 
functions include disulfide bonds, cleavable under reducing conditions (58-62); ester 
bonds, which hydrolyze upon time or can be cleaved by esterases (33, 60, 63, 64); 
pH-sensitive moieties as for example phosphoesters (65, 66), orthoesters (67), 
imines (34) or acetals/ketals (68, 69), disintegrating in acidic milieu. Figure 3 
schematically describes the concept of biodegradable gene vectors, exemplarily 
shown for an acid-sensitive polymer. 
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Figure 3. Generation of low-toxic, degradable gene vectors. Low m.w. 
polycations are polymerized via bifunctional linker molecules containing 
predetermined breaking points. Self-assembly of the resulting degradable polymers 
with the therapeutic nucleic acid leads to condensed polyplexes of nanometric size, 
which protect the compacted DNA from nucleases and mediate endocytosis. Upon a 
specific stimulus – in case of acid-sensitive linkage the endosomal acidification – the 
cleavage of the breaking points is triggered, inducing polymer degradation into small 
low toxic units. 
 
 
 
1.4 Aims of the thesis 
 
1.4.1 Synthesis and evaluation of a novel acetal-based PEGylation reagent for 
pH-sensitive shielding of polyplexes 
As reversible PEGylation was shown to improve properties of non-viral gene vectors 
considerably, but no suitable universally applicable reagents for acid sensitive 
PEGylation of polycations were available so far, it was our intention to design such a 
versatile PEGylation reagent. In contrast to the PEG-hydrazone linker mentioned 
above (50) this new reagent should be compatible also with polycations like PEI, 
thus permitting the exclusion of PLL from the complexes. Further it should be 
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compatible with various targeting ligands, to allow efficient polyplex uptake into the 
cell despite the PEG shield.  
The polymeric carriers Murthy et al. (55, 56) created by grafting hydrophilic PEG 
chains onto hydrophobic, membrane-disruptive methacrylate polymers, comprise 
acid-degradable p-amino-benzaldehyde acetals. These possess a suitable 
hydrolysis profile for hydrolysis at endosomal pH and therefore inspired us to choose 
as p-piperazino-benzaldehyde as staring point for our work. The aromatic aldehyde 
should be reacted with PEG alcohol to yield the corresponding acetal. Inclusion of a 
maleimido function (MAL) into the reagent should provide comfortable coupling of 
any desired thiol functionalized compound. 
In a second step, the benefit of polyplexes reversibly PEGylated with the new 
maleimido-modified PEG acetal reagent (PEG-A-MAL) over analogous stably 
shielded ones should be investigated in biophysical and cell culture experiments. 
 
1.4.2 Acetal linked, pH-degradable cationic carriers for reduced toxicity 
The second intention of this work was the generation of new polycations for use as 
gene vectors with improved biocompatibility features. Therefore, small non-toxic but 
inefficient OEI800 units should be reacted to larger oligomers or polymers via acid 
degradable linkers. As a result of the increased size, these products should mediate 
gene transfer efficiently while still being non-toxic due to their endosomal 
degradability. 
Acetal functions were chosen as predetermined breaking points, because of certain 
advantages: their acid-sensitivity makes them optimal agents for the targeting of 
endosomes as site of pH-induced cleavage. By adequate tailoring of their chemical 
properties, acetals allow to trigger polymer degradation exactly at a desired pH, such 
as the pH in endosomes. This would permit the production of vectors that are 
stabilized at physiological pH of 7.4 to mediate efficient transfer of nucleic acids from 
the circulation to the target cell. After endocytosis and endosomal acidification, when 
a high polymer m.w. is no longer needed, cleavage of the acid sensitive functions in 
the polymer would lead to vector degradation. 
As such cationic polymers with pH-degradable acetal backbone had not been 
described before, the aim was the synthesis, characterization and application of two 
types of acetal linked OEI800 based polymers: MK-OEI polymers which include 2,2-
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bis(N-maleimidoethyloxy) propane (MK) as pH-sensitive ketal linker (70), and BAA-
OEI polymers wherein OEI moieties are linked via the bisacrylate acetal 1,1-bis (2-
acryloyloxy ethoxy)-[4-methoxy-phenyl]methane) (BAA) (71). The advantage of the 
pH-sensitivity should be demonstrated by comparing the pH-labile polymers with 
homologous acid-stable polymers (BM-OEI and LT-OEI-HD), where the acid-
sensitive functions are replaced by a stable ether or a hydrocarbon moiety, 
respectively. Finally, on the basis of MK-OEI polymers the influence of changes in 
biophysical properties on the toxicity/transfection efficiency profile should be 
evaluated. 
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2 Materials and methods 
2.1 Chemicals and reagents 
 
Toluene and tetrahydrofuran (THF) were distilled from sodium benzophenone ketyl 
radical, dimethyl sufoxide (DMSO) was distilled and stored over molecular sieves 4 Å 
under nitrogen. Acetone, dichloromethane (DCM), diethyl ether, ethyl acetate 
(EtOAc), chloroform, n-heptane, n-hexane, methanol and N-ethyldimethylamine were 
distilled prior to use. Diethyl ether was stored over KOH. Methoxy poly(ethylene 
glycol)maleimide (PEG-MAL, average molecular weight of 5 kDa) and methoxy 
poly(ethylene glycol) thiol, average m.w. 5 kDa (PEG-SH) were purchased from 
Nektar Therapeutics (Huntsville Alabama). Poly(ethylene glycol) 5 kDa monomethyl 
ether (mPEG) was purchased from Fluka Chemie GmbH (CH-9471 Buchs) and dried 
by heating to reflux (water separator) in toluene at an oil bath temperature of 170 °C 
for 20 h prior to use.  Linear PEI of 22 kDa (PEI22K) was synthesized by acid-
catalyzed deprotection of poly(2-ethyl-2-oxazoline) (50 kDa, Aldrich) in analogous 
form as described (72). Branched PEI of 1.8 kDa (PEI1.8K) was purchased from 
Polyscience, Inc. Warrington, USA. Poly-L-lysine, hydrobromide, with average m.w. 
of 48 kDa and of 58 kDa (PLL48K and PLL58K), oligoethylenimine with an average 
molecular mass of 800 Da (OEI800), branched PEIs with average molecular weights 
of 2, 10, 25 and 50 kDa (PEI2K, PEI10K, PEI25K, PEI50K), hexyl acrylate (HA), 1,6-
hexanediol diacrylate (HD), p-methoxy-benzaldehyde, 2-hydroxyethyl acrylate, p-
toluene sulfonic acid and triethylamine (TEA) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Bafilomycin A1 was obtained from Alexis Biochemicals, CH-
4415 Lausen, Switzerland; 1,8-Bis-maleimidodiethyleneglycol (BM) was purchased 
from Pierce Biotechnology, Inc., Rockford, USA, and 2,2-Bis(N-maleimidoethyloxy) 
propane (MK) from Organix Inc., Woburn, Massachusetts, USA. MK can be also 
synthesized as described by Srinivasachar et al. (70). 1,1-Bis-(2-acryloyloxy ethoxy)-
[4-methoxy-phenyl]methane) (BAA) was synthesized following the protocol of Chan 
et al. (71). The resulting crude product was purified by flash column chromatography 
on silica gel equilibrated with the eluent (n-heptane/acetone 8.2/1.8 + 1 % TEA). 
BAA was obtained as a colorless oil with 100% purity as confirmed by 1H NMR. 
Targeting conjugates (EGF-PEI and Tf-PEI) contain the ligands EGF or Tf linked with 
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branched PEI25K by a heterobifunctional 3.4 kDa PEG linker and were synthesized 
as described previously (40, 41). Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) 
was purchased from Fluka (Steinheim, Germany). Bis-
(dibenzylideneacetone)palladium Pd(dba)2 was obtained from Sigma-Aldrich 
(Steinheim, Germany). Tris-(dibenzylideneacetone)dipalladium (Pd2(dba)3) was a gift 
from Prof. Dr. Lorenz, LMU (Munich, Germany). Cell culture media, antibiotics, fetal 
calf serum (FCS) were purchased from Life Technologies (Karlsruhe, Germany). 
Plasmid pCMVLuc (Photinus pyralis luciferase under control of the CMV enhancer / 
promoter) described in Plank et al. (73) was purified with the EndoFree Plasmid Kit 
from Qiagen (Hilden, Germany).  
 
General information on chemicals, methods and equipment 
Water was used as purified, deionized water. All chemical procedures – except 
polymerization reactions – were carried out in oven-dried glassware under inert gas 
atmosphere (nitrogen or argon) unless stated otherwise. All reagents were 
purchased from commercial suppliers and used without further purification if not 
specified otherwise. To avoid stressing conditions during the polymerization 
reactions, all polymer syntheses were carried out under argon atmosphere in 
Eppendorff vials, in anhydrous DMSO. The reaction mixtures were kept at room 
temperature and were protected from light during the entire reaction time. Dialysis 
was performed with Spectra/Por membranes (molecular mass cut off 3.5 kDa or 
molecular mass cut off 6-8 kDa; Spectrum Laboratories Inc., Rancho Dominguez, 
CA, USA) at 4 °C. Infrared spectra were recorded on a Perkin Elmer FT-IR 
Spectrometer Paragon 1000 or on a Jasco FT/IR-410 spectrometer (Jasco Labor- 
und Datentechnik GmbH, Deutschland). 1H NMR spectra were recorded on a Jeol 
JNMR-GX400 (400 MHz) or on a Jeol JNMR-GX500 (500 MHz) spectrometer. 
Chemical shifts are reported in ppm and refer to the solvent as internal standard 
(CH2Cl2 at 5.32 ppm, DMSO at 2.52 ppm, H2O at 4.8 ppm). Data are reported as s = 
singulet, d = doublet, t = triplet, m = multiplet; coupling constants in Hz; integration. 
13C NMR spectra were recorded on a Jeol JNMR–GX500 (125 MHz) spectrometer. 
Chemical shifts are reported in ppm using solvent as an internal standard (CD2Cl2 at 
5.38 ppm). Mass spectra were obtained on a Hewlett Packard 5989A MS Engine 
with 59980B Particle Beam and on a Jeol MStation JMS-700. UV absorption and UV 
spectra were recorded on a GENESYSTM 10 Series Spectrometer (Thermo Electron 
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Corporation, Pittsford; NY). Column chromatography was performed on Merck silica 
gel 60 Å (40-63 µm). Gel filtration was performed on Sephadex G-25 superfine (20 
mM Hepes buffer pH 7.4 with 0.25 M NaCl, at a flow rate of 1 mL/min), Superdex 75 
prep grade or Superdex 200 prep grade (buffer as indicated respectively, at a flow 
rate of 1 mL/min) using a HR 10/30 column (Pharmacia, Sweden). Cation-exchange 
was performed on a HR 10/10 column (BioRad, Munich, Germany) filled with Macro-
prep High S. 
 
2.2 Design and synthesis of the acetal-based pH-sensitive 
PEGylation reagent PEG-A-MAL  
2.2.1 Development of the synthesis on the basis of the dummy ME-A-MAL  
1-[Bis-(2-methoxyethoxy)methyl]-4-bromobenzene (1). p-Bromobenzaldehyde 
(1.85 g, 10 mmol), p-TsOH·H2O (19 mg, 0.1 mmol) and 2-methoxyethanol (1.66 ml, 
21 mmol) were heated at 85 °C in CHCl3 (50 ml) for 22 h by continuous removal of 
water. After cooling to r.t. a 20-fold excess of K2CO3 (0.2764 g, 2 mmol) was added 
and the reaction mixture was stirred for 1 h, then filtered and the solvent was 
removed under reduced pressure. The resulting residue was taken up in CH2Cl2, 
fixed onto silica gel and purified by column chromatography (n-
hexane/EtOAc/CH2Cl2 = 9/0.5/0.5 + 1 % N-ethyldimethylamine) to afford 1 as yellow 
oil (1.41 g, 44 %). 
IR (film): 2979, 2925, 2877, 2818, 1592 cm-1; 1H NMR (500 MHz, CD2Cl2): δ = 3.33 
(s, 6 H), 3.52 (t, J  = 5 Hz, 4 H), 3.58-3.67 (m, 4 H), 5.55 (s, 1 H), 7.35-7.38 (m, 2 H), 
7.48-7.51 (m, 2 H); 13C NMR (125 MHz, CD2Cl2): δ = 59.0 (CH3), 65.1 (CH2), 72.2 
(CH2), 101.5 (CH), 122.7, 129.0, 131.6, 138.3 (Carom.); MS (DEI+): m/z (%) = 320 (1) 
[M+H+], 59 (100). 
Br
OO
OMeMeO
 
 1 
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2-Trimethylsilylethyl piperazine-1-carboxylate (2). To a solution of piperazine 
(260 mg, 3.0 mmol) in H2O (3 ml) a solution of NEt3 (0.632 ml, 4.5 mmol) in dioxane 
(3 ml) and a solution of 1-[2-(trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dion (39 
mg, 1.5 mmol) in dioxane (3 ml) were  added at r.t. subsequently. After stirring for 24 
h the reaction mixture was treated with a saturated solution of NaHCO3 (20 ml) and 
extracted with EtOAc (5 x 20 ml). The combined organic layers were dried  (MgSO4), 
filtered  and concentrated under reduced pressure. The resulting residue was 
purified by column chromatography (EtOAc/CH2Cl2/MeOH = 5/4/2 + 1 % N-
ethyldimethylamine) to afford 2 as colorless oil (211 mg, 61 %). 
1H NMR (500 MHz, CDCl3): δ = 0.02 (s, 9 H), 0.10 (t, J = 8.3 Hz, 2 H), 2.80-2.85 (m, 
4 H), 3.42-3.48 (m, 4 H), 4.17 (t, J = 8.3 Hz, 2 H); MS (CI): m/z (%) = 231 (9) [M+H+], 
203 (100).   
NH
N
O
O
Si
 
      2 
 
2-Trimethylsilylethyl 4-(4-{1-[bis(2-methoxyethoxy)]methyl}phenyl)piperazine-
1-carboxylate (3). A solution of 2 (30.6 mg, 0.1328 mmol) and 1 (32.4 mg, 0.1014 
mmol) in toluene (2 ml) was added to KOtBu (17.1 mg, 0.1521 mmol), bis-
(dibenzylideneacetone)palladium (5.8 mg, 0.0101mmol) and 2-
(dicyclohexylphosphino)biphenyl (3.6 mg, 0.0101 mmol) and stirred at 90 °C for 18 
h. After cooling to r.t. the mixture was treated with a saturated solution of NaHCO3 (4 
ml). The aqueous solution was extracted with CH2Cl2 (5 x 8 ml), the combined 
organic layers were dried (MgSO4), filtered and  evaporated under reduced pressure. 
The resulting crude product was purified by column chromatography (equilibration 
with n-hexane/EtOAc/CH2Cl2 = 7/2/1 + 1 % N-ethyldimethylamine; eluent: n-
hexane/EtOAc/CH2Cl2 = 7/2/1 + 0.5 % N-ethyldimethylamine) to afford 3 (38.0 mg, 
80 %) as yellow oil . 
IR (film): 2951, 2891, 2820, 1698, 1613 cm-1; 1H NMR (500 MHz, CD2Cl2): δ = 0.04 
(s, 9 H), 1.01 (m, 2 H), 3.13 (t, J = 5.1 Hz, 4 H), 3.33 (s, 6 H), 3.49-3.67 (m, 12 H), 
4.18 (m, 2 H), 5.49 (s, 1 H), 6.87-6.93 (m, 2 H), 7.30-7.36 (2 H); 13C NMR (100 MHz, 
CD2Cl2): δ = -1.4 (CH3), 18.0 (CH2), 44.0 (CH2), 49.5 (CH2), 59.0 (CH3), 63.8 (CH2), 
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64.8 (CH2), 72.2 (CH2), 102.1 (CH), 116.1, 127.9, 130.4, 151.7 (Carom.), 155.7 (C); 
MS (ESI+): m/z (%) = 469 (53) [M+H+], 393 (100), 491 (94) [M+Na+]; UV (20 mM 
Hepes buffer pH 7.4/MeOH =  8/2): λmax = 246 nm. 
 
OO
OMeMeO
N
N
OO
Si
  
       3 
 
1-(4-{1-[Bis(2-methoxyethoxy)]methyl}phenyl)piperazine (4). A solution of 
TBAF·3H2O (30.2 mg, 0.0956 mmol) in THF (2 ml) was added dropwise to a stirred 
solution of 3 (22.4 mg, 0.0478 mmol) in THF (2 ml) at r.t.. After stirring for 24 h the 
reaction mixture was treated with a saturated solution of NaHCO3 (5 ml), extracted 
with CH2Cl2 (5 x 5 ml) and the combined organic layers were dried (MgSO4), filtered 
and the solvent was removed under reduced pressure. The resulting residue was 
purified by column chromatography (EtOAc/CH2Cl2 = 5/5 + 5 % N-
ethyldimethylamine). The fractions containing 4 were contaminated with a salt 
derived from silicagel and N-ethyldimethylamine. For further purification they were 
evaporated and the resulting residue was extracted several times with EtOAc to 
separate the desired product from the EtOAc-insoluble salt. The combined EtOAc 
extracts were evaporated to afford 4 as a pale yellow oil (12.7 g, 82 %). 
IR (film): 2925, 2879, 2820, 1613, 1518 cm-1; 1H NMR (500 MHz, CD2Cl2): δ = 2.66 
(m, 2 H), 2.98-3.03 (m, 2 H), 3.12-3.21 (m, 4 H), 3.33 (s, 6 H), 3.50-3.66 (m, 8 H); 
13C NMR (100 MHz, CD2Cl2): δ = 46.2 (CH2), 49.3 (CH2), 50.2 (CH2), 51.8 (CH2), 
59.9 (CH3), 64.9 (CH2), 72.2 (CH2), 102.3 (CH), 115.4, 127.8, 129.5, 152.0 (Carom.). 
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OMeMeO
N
N
H   
        4 
 
N-{3-[4-(4-{1-[bis-(2-methoxyethoxy)]methyl}phenyl)piperazinyl]-3- oxopropyl} 
maleimide (ME-A-MAL) (5). To a stirred solution of 4 (8.6 mg, 0.0265 mmol) in 
DMSO (0.5 ml) N-methylmorpholine (3 µl, 0.0265 mmol) and 3-(maleimido)propionic 
acid N-hydroxysuccinimide ester (7.1 mg, 0.0265 mmol) were added subsequently at 
r.t.. After stirring for 2 h the reaction mixture was treated with phosphate buffer pH 
7.4 [2 ml; KH2PO4 (250.0 ml, 0.2 M) + NaOH (393.4 ml, 0.1 M)] and extracted with 
EtOAc (4 x 4 ml). The combined organic layers were dried (MgSO4), filtered and 
evaporated. The resulting crude product was purified by column chromatography 
(CH2Cl2/EtOAc = 7/3 + 1 % N-ethyldimethylamine) to afford 5 as yellow oil (6.9 mg; 
55 %). 
1H NMR (500 MHz, CD2Cl2): δ = 2.64-2.73 (m, 2 H), 3.11-3.20 (m, 4 H), 3.33 (s, 6 
H), 3.50-3.54 (m, 4 H), 3.54-3.66 (m, 8 H), 3.68-3.76 (m, 2 H), 3.78-3.84 (m, 2 H), 
5.49 (s, 1 H), 6.69 (s, 2 H), 6.83-6.92 (m, 2 H), 7.31-7.36 (m, 2 H); 
 
OO
OMeMeO
N
N
N
O
O
O
  
   5 
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2.2.2 Synthesis of PEG-A-MAL  
1-(4-Bromobenzene)-1-{bis[monomethoxypoly(ethylenoxy)]}methane (6). p-
Bromobenzaldehyde (5.5506 g, 30 mmol) and p-TsOH·H2O (19 mg, 0.1 mmol) were 
added to dried mPEG5K (10.0 g, 2 mmol) in toluene (50 ml), and the stirred reaction 
mixture was heated for 22 h at 170 °C (oil bath temperature). K2CO3 (276 mg, 2 
mmol) was added and after 45 min of stirring at room temperature (r.t.) the solidified 
reaction mixture was diluted with with CH2Cl2, filtered and evaporated. For 
purification the crude product was powdered, washed with Et2O (7 x) and finally 
dried under vacuum to afford 6 as a white powder (9.860 g, 97 %). 
1H NMR (500 MHz, CD2Cl2): δ = 3.32 (s, CH3 PEG5K), 3.37-3.79 (m, CH2 PEG5K), 
5.56 (s, 1 H), 7.34-7.40 (m, 2 H), 7.45-7.52 (m, 2 H). 
 
2-Trimethylsilylethyl 4-[4-(1{bis[monomethoxypoly(ethylenoxy)]}methyl)phenyl] 
piperazine-1-carboxylate (7). The following synthesis steps were carried out under 
an argon atmosphere. KOtBu (19.1 mg, 0.17 mmol), Pd2(dba)3 (4.6 mg, 0.005 mmol), 
2-(dicyclohexylphosphino)biphenyl and dried 6 (1.0167 g, 0.1 mmol) were suspended 
in toluene (1 ml). A solution of 2-trimethylsilylethyl piperazine-1-carboxylate (2, 
Supporting information) (34.5 mg, 0.15 mmol) in toluene (1 ml) was added and the 
reaction mixture was stirred for 45 h at 90 °C. After cooling to r.t. the mixture was 
treated with a saturated solution of NaHCO3 (20 ml). The aqueous solution was 
extracted with CH2Cl2 (7 x 15 ml), the combined organic layers were dried (MgSO4), 
filtered and evaporated under reduced pressure. To remove impurities the resulting 
crude product was powdered and extracted with Et2O (5 x) to give 7 as a fawn powder 
(918 mg, 90 %). The 1H NMR shows this product contained about 82 % of  7 and 18 
% of unreacted 6, which could not be eliminated but also did not interfere in the 
following synthesis steps. 
1H NMR (500 MHz, CD2Cl2): δ = 0.04 (s, 9 H), 0.98-1.03 (m, 2 H), 3.13 (t, J = 5.0 Hz, 
4 H), 3.32 (s, CH3 PEG5K), 3.42-3.75 (m, CH2 PEG5K, 4 H), 4.13-4.20 (m, 2 H), 
5.50 (s, 1 H),  6.87-6.92 (m, 2 H), 7.31-7.36 (m, 2 H). 
 
1-[4-(1-{Bis[monomethoxy poly(ethylenoxy)]}methyl)phenyl]piperazine (8). To a 
suspension of  7 (310 mg, 0.03 mmol) in THF (1 ml) a solution of  tetrabutyl 
ammonium fluoride trihydrate (TBAF·3H2O) in THF (1 ml) was added dropwise. After 
slightly warming the reaction mixture, it was stirred at r.t. for 20 h. The mixture was 
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then treated with a saturated solution of NaHCO3 (5 ml). The aqueous solution was 
extracted with CH2Cl2 (5 x), the combined organic layers were dried (MgSO4), filtered 
and evaporated under reduced pressure. The resulting solid was powdered and 
washed with Et2O (5 x 10 ml) to afford 8 as a beige powder (275.5 mg, 90 %). 
1H NMR (500 MHz, CD2Cl2): δ = 2.94-2.99 (m, 4 H), 3.07-3.12 (m, 4 H), 3.33 (s, CH3 
PEG5K), 3.42-3.76 (m, CH2 PEG5K), 5.49 (s, 1 H), 6.84-6.90 (m, 2 H), 7.28-7.33 (m, 
2 H). 
 
N-(3-{4-[4-(1-{Bis[monomethoxy poly(ethylenoxy)]}methyl)phenyl] piperazinyl-} 
3-oxopropyl) maleimide (9). N-Methylmorpholin (11 µl, 0.1 mmol) and N-
succinimidyl-3-maleimidopropionate (13 mg, 0.05 mmol) were added subsequently 
to a suspension of 8 (101.9 mg, 0.01 mmol) in DMSO (0.5 ml) and stirred at r.t. for 
30 min. The reaction mixture was then treated with phosphate buffer pH 7.4 [3 ml; 
KH2PO4 (250.0 ml, 0.2 M) + NaOH (393.4 ml, 0.1 M)] and extracted with CH2Cl2 (5 x 
5 ml). The combined organic layers were dried (MgSO4), filtered and evaporated. 
The resulting beige solid was aliquoted into two portions of about 50 mg, dissolved in 
20 mM Hepes buffer pH 7.4 with 0.25 M NaCl (2 ml) and purified by gel filtration 
chromatography (G-25 superfine). The fractions containing the desired product were 
extracted with CH2Cl2 (5 x 5 ml). The combined organic layers were dried (MgSO4), 
filtered and evaporated under reduced pressure to give 9 as a pale yellow solid (73.5 
mg, 71 %). 
1H NMR (500 MHz, CD2Cl2): δ = 2.63-2.70 (m, 2 H), 3.11-3.20 (m, 2 H), 3.32 (s, 6 
H), 3.42-3.82 (m, CH2 PEG5K, 4H, 4 H), 5.50 (s, 1 H), 6.69 (s, 2 H), 6.86-6.91 (m, 2 
H), 7.32-7.36 (m, 2 H).  
 
 
2.3 PEGylation of polycations 
 
2.3.1 Thiolation 
Thiolation of branched polyethylenimine. PEI25K (6 mg, 0.24 µmol) in 0.1 M 
Hepes buffer pH 7.4 (0.4 ml) was mixed with 0.6 µmol SPDP from a stock at 3 
mg/mL in DMSO. The reaction was mixed over night at room temperature and the 
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resulting product was purified by G-25 superfine gel filtration (74, 75). The 
dithiopyridyl groups of the product were reduced with 50 mol equivalents of DTT for 
10 min and the resulting thiol modified PEI25K was purified by G-25 superfine gel 
filtration equilibrated in 20mM Hepes pH 7.4 containing 0.25 M NaCl under argon. 
The product was snap frozen in liquid nitrogen and stored at -80 °C. PEI25K was 
quantified by the 2,4,6-trinitrobenzenesulfonic acid (TNBS) assay (76) and the 
amount of free mercapto groups was determined by the Ellman`s assay (77). 
Thiolation of poly-(L-lysine) (PLL58K), linear polyethylenimine (PEI22K), HT-
OEI-HD1. PLL58K, PEI22K and HT-OEI-HD1 were thiolated in analog manner to 
PEI25K. Quantification of polycation in the product was performed by TNBS assay, 
thiol groups were quantified by Ellman´s assay. 
 
2.3.2 PEGylation: poly(ethylene glycol)-polycation conjugates 
Poly(ethylene glycol)-polyethylenimine conjugates. PEG-A-MAL 9 (0.2 ml, 0.12 
µmol) for acid reversible conjugates, or PEG-MAL (0.1 ml, 0.2 µmol) for acid-stable 
conjugates were dissolved in degassed 20 mM Hepes buffer pH 7.4 containing 0.25 
M NaCl by brief sonication. PEG-A-MAL or PEG-MAL was mixed with PEI25K-SH at 
0.03 or 0.02 µmol (PEI), respectively (total volume 2 ml). After 10 min the reaction 
was applied to the cation-exchange column which was equilibrated in 20 mM Hepes 
buffer pH 7.4 containing 0.5 M NaCl. The salt concentration was increased with a 
linear gradient to 3 M NaCl (10 min) and maintained at 3 M NaCl for 15 min with a 
flow rate of 1 ml/min. The PEI25K product was eluted as a single peak at 3M NaCl. 
PEI25K was quantified by the TNBS assay. PEG-conjugation was monitored by 
measuring unbound PEG (78) and by 1H NMR. The purified conjugates (PEG-A-
PEI25K and PEG-S-PEI25K) were snap frozen in liquid nitrogen and stored at -80 
°C.  
PEGylation of PLL58K, PEI22K, HT-OEI-HD1. For acid reversible PEGylation the 
thiolated polycations were reacted with PEG-A-MAL 9 as described above for 
PEI25K-SH. 
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2.4 Synthesis of acetal linked acid-degradable MK polymers, 
stable BM control polymers, and their derivatives 
 
2.4.1 Synthesis of pH-stable dummy polymer BM-A1/1 
BM (15.4 mg; 50 mg/mL in DMSO) was added dropwise and under vortexing to 
OEI800 (40 mg; 400 mg/mL in DMSO) and reacted for 22 h at room temperature 
under constant shaking. Prior to purification, the reaction mixture was diluted 1:4 with 
1M Hepes buffer pH 7.5 containing 4 M sodium chloride. Dialysis was carried out at 
4 °C in 20 mM Hepes buffer pH 7.5 containing 0.25 M sodium chloride using a 
Spectra/Por membrane (molecular mass cut off 3.5 kDa). After 4 h the buffer was 
exchanged against water; water was then replaced twice by fresh water. After a total 
dialysis duration of 26 h the purified product was lyophilized (yield 48 %) and stored 
at -80 °C. According to 1H NMR analysis, the molar ratio of BM to OEI800 in the 
product was 1.3/1. 
1H NMR (500 MHz, D2O): δ = 3.77 (t, 4H, NCH2CH2O), 3.69 (s, 4H, OCH2CH2O 
linker ethylene), 3.64 (t, 2H, COCHCH2 of linker succinimide), 3.59-2.35 (br m; 72H 
NCH2 of OEI ethylenes; 4H NCH2CH2O of linker ethylenes and 4H COCH2CH of 
linker succinimide).  
 
2.4.2 Synthesis of pH-stable dummy polymer BM-B1/1 
The polymer was synthesized in an analog manner as BM-A1/1. Therefore, BM (15.4 
mg; 50 mg/mL in DMSO) was added dropwise and under vortexing to PEI1.8K (90 
mg; 600 mg/mL in DMSO) and reacted for 22 h at room temperature under constant 
shaking. Prior to purification, the reaction mixture was diluted 1:4 with 1 M Hepes 
buffer pH 7.5 containing 4M sodium chloride and dialyzed at 4 °C using a 
Spectra/Por membrane (molecular mass cut off 6-8 kDa) for 26 h as described 
above. After dialysis, the purified product was lyophilized and stored at -80 °C (yield 
68 %). According to 1H NMR analysis, the molar ratio of BM to PEI1.8K in the 
product was 1.3/1. 
1H NMR (400 MHz, D2O): δ = 3.72 (t, 4H, NCH2CH2O), 3.69-3.54 (m, 4H, 
OCH2CH2O linker ethylene; 2H, COCHCH2 of linker succinimide), 3.54-2.30 (br m; 
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162H, NCH2 of PEI ethylenes; 4H NCH2CH2O of linker ethylenes and 4H COCH2CH 
of linker succinimide). 
 
2.4.3 Synthesis of pH-stable dummy polymer PEG-BM-A1/1 
A solution of PEG-SH (14.2 mg; 333 mg/mL in DCM) was added dropwise and under 
vortexing to a 19-fold excess of BM (15.4 mg; 50 mg/mL in DMSO). After mixing the 
components thoroughly, the solution was added dropwise and under vortexing to 
OEI800 (38 mg; 400 mg/mL in DMSO) and reacted for 22 h at room temperature 
under constant shaking. Prior to purification, the reaction mixture was diluted 1:4 with 
1 M Hepes buffer pH 7.5 containing 4 M sodium chloride. Then dialysis was carried 
out at 4 °C in 20 mM Hepes buffer pH 7.5 containing 0.25 M sodium chloride using a 
Spectra/Por membrane (molecular mass cut off 3.5 kDa). After 4 h the buffer was 
substituted for water; water was then replaced twice by fresh water. After total 
dialysis duration of 26 h, the purified product was lyophilized and stored at -80 °C 
(yield 68 %). According to 1H NMR analysis, the molar ratio of PEG to BM to OEI800 
in the product was 0.05/1.3/1; 
1H NMR (500 MHz, D2O): δ = 3.73 (t, 4H, NCH2CH2O), 3.67 (s, 472H OCH2CH2O of 
PEG ethylenes), 3.67 (s, 4H, OCH2CH2O linker ethylene), 3.60 (t, 2H, COCHCH2 of  
linker succinimide), 3.58-2.35 (br m; 72H NCH2 of OEI ethylenes; 4H NCH2CH2O of 
linker ethylenes and 4H COCH2CH of  linker succinimide). 
 
2.4.4 Synthesis of acid-degradable polymers MK-A1/1, MK-A1.2/1, MK-A1.5/1 
MK (16.1 mg, 19.32 mg, or 24.15 mg respectively; 50 mg/mL in DMSO) was added 
dropwise and under vortexing to OEI800 (40 mg; 400 mg/mL in DMSO) and reacted 
for 22 h at room temperature while shaking constantly. Quenching, purification and 
lyophilization were performed as indicated above for BM-A1/1, unless for dialysis of 
MK-A1.2/1 and 1.5/1, where the 3.5 kDa Spectra/Por membrane was exchanged by 
a 6-8 kDa cut off membrane. Dry polymers were stored at -80 °C (yields were 40 % 
for MK-A1/1, 51% for MK-A1.2/1 and 60 % for MK-A1.5/1 polymer). According to 1H 
NMR analysis molar ratios of MK linker acetals versus OEI800 in the product were 
0.93/1 (MK-A1/1), 1.05/1 (MK-A1.2/1) and 1.23/1 (MK-A1.5/1).   
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1H NMR (400 MHz, D2O): δ = 3.75 (t, 4H, OCH2), 3.72-2.30 (br m; 72H NCH2 of OEI 
ethylenes; 10H NCH2 of linker ethylene and COCHCH2 of linker succinimide), 1.45-
1.25 (m, 6H, CH3 of linker acetone ketal). 
 
2.4.5 Synthesis of acid-degradable MK-B1/1 
 MK (16.1; 50 mg/mL in DMSO) was added dropwise and under vortexing to PEI1.8K 
(90 mg; 600 mg/mL in DMSO) and reacted for 22 h at room temperature under 
constant shaking. Prior to purification, the reaction mixture was diluted 1:4 with 1 M 
Hepes buffer pH 7.5 containing 4 M sodium chloride and dialyzed at 4 °C using a 
Spectra/Por membrane (molecular mass cut off 6-8 kDa) for 26 h as described 
above. After a total dialysis duration of 26 h, the purified product was lyophilized and 
stored at -80 °C (yield 43 %). According to 1H NMR analysis, the molar ratio of MK 
linker acetals to PEI1.8K in the product was 0.93/1. 
1H NMR (400 MHz, D2O): δ = 3.77 (t, 4H, OCH2), 3.81-2.40 (br m; 162H NCH2 of PEI 
ethylenes; 14H NCH2CH2O of linker ethylene and COCHCH2 of  linker succinimide), 
1.45-1.24 (m, 6H, CH3 linker). 
           
2.4.6 Synthesis of acid-degradable PEG-MK-A1/1 
A solution of PEG-SH (14.2 mg; 333 mg/mL in DCM) was added dropwise and under 
vortexing to MK (16.0 mg; 50 mg/mL in DMSO). After mixing the components 
thoroughly, the solution was added dropwise and under vortexing to OEI800 (38 mg; 
400 mg/mL in DMSO) and reacted for 22 h at room temperature under constant 
shaking. Quenching, purification and lyophilization were performed as indicated 
above for PEG-BM-A1/1 (yield 43 %). According to 1H NMR analysis, the molar ratio 
of PEG to MK to OEI800 in the product was 0.08/1.09/1. 
1H NMR (400 MHz, D2O): δ = 3.86-2.30 (br m; 472H OCH2CH2O of PEG ethylene; 
72H NCH2 of OEI ethylenes; 14H NCH2CH2O of linker ethylene and COCHCH2 of 
linker succinimide), 1.45-1.25 (m, 6H, CH3 linker). 
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2.4.7 Synthesis of acid-degradable HA2.5-MK-A1/1, HA5-MK-A1/1, HA10-MK-
A1/1 
MK-A1/1 was synthesized following the protocol above. After the reaction time of 22 
h a 2.5-, 5- or 10-fold molar amount (related to molar amount of OEI800) of hexyl-
acrylate (19.5mg, 22.0 µl; 39.1 mg, 44.0 µl; or 78.1mg, 88.0 µl respectively)  was 
added and the mixture was kept on the shaker at 40 °C for another 3 h. Prior to 
purification, the reaction mixture was diluted 1:4 with 1 M Hepes buffer pH 7.5 
containing 4 M sodium chloride and dialyzed at 4 °C using a Spectra/Por membrane 
(molecular mass cut off 3.5 kDa) for 26 h as described above. After total dialysis 
duration of 26 h, the purified product was lyophilized and stored at -80 °C (yield 66 
%, 70 % and 84 % for HA2.5-, HA5- and HA10-MK-A1/1 respectively). According to 
1H NMR analysis, the molar ratios of HA/MK/OEI in the products were 1.4/0.93/1 
(HA2.5-MK-A1/1), 3.6/0.93/1 (HA5-MK-A1/1) and 7.0/0.93/1 (HA5-MK-A1/1). 
1H NMR (500 MHz, DMSO-d6): δ =  4.08-3.96 (m; 2H COOCH2 HA-ester), 3.53 (s; 
472H OCH2CH2O of PEG ethylene), 3.49-2.20 (m; 72H NCH2 of OEI ethylenes; 14H 
NCH2CH2O of linker ethylene and COCHCH2 of linker succinimide; 4H 
NCH2CH2COO of HA), 1.64-1.45 (m; 2H COOCH2CH2 HA-ester); 1.39-1.12 (m; 6H 
CH2CH2CH2CH3 of HA; 6H, CH3 linker), 0.96-0.76 (m; 3H CH3 HA); 
 
2.4.8 Synthesis of acid-degradable HA2.5-PEG-MK-A1/1, HA5-PEG-MK-A1/1, 
HA10-PEG-MK-A1/1 
PEG-MK-A1/1 was synthesized following the protocol above. After the reaction time 
of 22 h a 2.5-, 5- or 10-fold molar amount (related to molar amount of OEI800) of 
hexyl acrylate (18.6mg, 20.9 µl; 37.1 mg, 41.8 µl; or 74.2mg, 83.6 µl respectively)  
was added and the mixture was kept on the shaker at 40 °C for another 3 h. Prior to 
purification, the reaction mixture was diluted 1:4 with 1 M Hepes buffer pH 7.5 
containing 4 M sodium chloride and dialyzed at 4 °C using a Spectra/Por membrane 
(molecular mass cut off 3.5 kDa) for 26 h as described above. After total dialysis 
duration of 26 h, the purified product was lyophilized and stored at -80 °C (yield 62 
%, 74 % and 47 % for HA2.5-, HA5- and HA10-PEG-MK-A1/1 respectively). 
According to 1H NMR analysis, the molar ratios of HA/PEG/MK/OEI in the products 
were 1.3/0.084/1.09/1 (HA2.5-PEG-MK-A1/1), 3.6/0.047/1.09/1 (HA5-PEG-MK-A1/1) 
and 7.4/0.041/1.09/1 (HA5-PEG-MK-A1/1). 
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1H NMR (500 MHz, DMSO-d6) δ =  4.05-3.96 (m; 2H COOCH2 HA-ester), 3.50-2.11 
(m; 72H NCH2 of OEI ethylenes; 14H NCH2CH2O of linker ethylene and COCHCH2 
of  linker succinimide; 4H NCH2CH2COO of HA), 1.61-1.52 (m; 2H COOCH2CH2 HA-
ester); 1.37-1.16 (m; 6H CH2CH2CH2CH3 of HA; 6H, CH3 linker), 0.92-0.83 (m; 3H 
CH3 HA). 
 
 
 
2.5 Synthesis of ketal linked acid-degradable BAA polymers  
 
2.5.1 Synthesis of acid-degradable BAA-1/1-3d, -1.5d, -45min, BAA-2/1-3d and 
BAA-1.25/1-45min-hc 
BAA (14 mg (for synthesis of BAA-1/1 polymers) and 28 mg (for synthesis of BAA-
2/1), each 50 mg/mL in DMSO; or 17.5 mg (for synthesis of BAA-1/1-45min-hc), 500 
mg/mL in DMSO) was added dropwise and under vortexing to OEI800 (32 mg; 400 
mg/mL in DMSO) and reacted for 3 days (BAA-1/1-3d, BAA-2/1-3d), 1.5 days (BAA-
1/1-1.5d) or 45 min (BAA-1/1-45min, BAA-1.25/1-45min-hc) at room temperature 
with constant shaking. Quenching, purification (total dialysis duration was only 15 h 
to prevent high extents of aminolysis) and lyophilization were performed as indicated 
above for BM-A1/1. The yields were 40 %, 56 % and 70 % in case of BAA-1/1-3d, -
1.5d and -45min, respectively; 50 % yield in case of BAA-2/1-3d and 58 % in case of 
BAA-1.25/1-45min-hc. Polymers were stored at -80 °C. According to 1H NMR 
analysis the molar ratios of BAA linker versus OEI800 in the products were 0.3/1 
(BAA-1/1-3d) and 0.7/1 (BAA-2/1-3d), the content of intact diester therein was 26 % 
for BAA-1/1-3d and BAA-2/1-3d; if reaction time was shortened to 1.5 days (BAA-
1/1-1.5d), the BAA/OEI ratio was 0.4 with a diester content of 40 %. Reduction of the 
reaction time to 45 min increased the ratio to 0.44 with 75 % diester (BAA-1/1-45min) 
and 0.56 with 60 % diester (BAA-1.25/1-45min-hc). 1H NMR spectra of the purified 
polymers, which were recorded in D2O, gave the following identification: 
1H NMR (400 MHz, D2O): δ =  7.50-7.37 (m, 2H, CH CHCOCH3 of aromatic ring), 
7.08-6.96 (m, 2H, CH COCH3 of aromatic ring), 5.68-5.53 (m; 1H, acetal H), 4.35-
4.28 (m,  COOCH2; 2H, monoester* or 4H, diester), 4.00-2.30 (br m; 72H NCH2 of 
OEI ethylenes; 3H, OCH3; 4H, OCH2CH2OCO; 2H, OCH2CH2OH*; 8H, OOCCH2CH2 
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and NOCCH2CH2*). *Due to partial ester hydrolysis and aminolysis, resulting in 
corresponding alcohol and the carboxylic acid or amide.  
 
2.5.2 Synthesis of LT-OEI-HD polymer 
Synthesis of LT-OEI-HD was performed following the protocol of Kloeckner et al. 
(79). HD-linker and OEI800 were employed in the synthesis at a molar ratio of 1.2/1 
(HD/OEI800). 
 
 
 
2.6 Polymer characterization methods 
 
2.6.1 Trinitrobenzenesulfonic acid (TNBS) assay  
Concentration of PLL, PEI, PEI conjugates and BAA polymers was measured by 
trinitrobenzenesulfonic acid (TNBS) assay as described in (76). In a 96-well plate 
standard solutions of PLL, PEI or OEI800, respectively, with a defined polymer 
concentration, and test solutions containing the samples were serially diluted in 
duplicates with 0.1 M sodium tetraborate to give a final volume of 100 µl. Applied 
standard polymer concentrations ranged from 0 to 60 µg/ml, in steps of 10 µg/ml. 2.5 
µl of TNBS (75 nmol) diluted in water was added to each well. After a reaction time 
of 5 minutes at room temperature, absorption was measured at 405 nm using a 
microplate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). 
 
2.6.2 Copper complex assay 
Quantification of OEI800- or PEI1.8K-based polymers (except BAA-polymers) was 
performed by a copper complex assay described in (80): 50 µl of copper-(II)-sulfate 
dissolved in 0.1 M sodium acetate (0.23 mg/ml) of pH 5.4 were mixed with either 50 
µl of aqueous standard OEI800/PEI1.8K dilutions of known concentrations (standard 
curve) or with 50 µl of the OEI/PEI1.8K-based polymer solutions. The resulting 
Cu(II)/amine complexes were quantified by measuring the absorbance at 285 nm 
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using a GENESYSTM 10 Series Spectrometer (Thermo Electron Corporation, 
Pittsford, NY).  
 
2.6.3 Analysis of aminolysis kinetics by 1H NMR 
Synthesis of BAA-1/1 was performed as indicated above but by exchanging DMSO 
by DMSO-d6. The reaction mixture was analyzed by 1H NMR at different time points 
between 0.5 h and 24 d. The degree of amininolysis was calculated by analyzing the 
signal of the acetal proton at 5.5 ppm, which shows a shift towards the higher field 
when aminolysis occurs. 
  
2.6.4 Size exclusion chromatography (SEC) for determination of polymer 
molecular weight and for polymer fractionation 
Gel filtration was performed on Superdex 75 or a Superdex 200 material (GE 
Healthcare Bio Sciences AB, SE-75184 Uppsala) using a HR 10/30 column 
(Pharmacia, Sweden) with an HPLC 600 controller equipped with a photodiode array 
detector 996 from Waters (Waters GmbH Eschborn, Germany). Column material 
was preconditioned with PEI25K prior to use to saturate residual ionic functions, 
which might interact with amine containing samples and impair the results. 20 mM 
Hepes buffer pH 7.4 with 0.25 M NaCl was chosen as running buffer. Samples were 
dissolved in the running buffer and applied to the column filled with either Superdex 
75 material for determinations in the low molecular weight or Superdex 200 for the 
analysis in the high molecular weight range. Runs were performed at a flow rate of 1 
mL/min and sample detection was carried out at λ = 225 nm and 254 nm. 
Polymer fractionation (MK-A1/1, MK-B1/1) was performed analogously using a 
Superdex 75 column and 20 mM Hepes buffer pH 7.8 with 0.25 M NaCl as solvent 
and running buffer. The polymers were separated into three fractions, starting with 
Fr.I which comprises the polymer-portion eluting between minute 9 and 15, followed 
by Fr.II ranging from minute 16 to 20 and finally closing with Fr.III, containing 
monomers eluting after 21 minutes and later.  
For determination of the acid degradability of BAA polymers, the polymers were 
diluted in 20 mM Hepes and adjusted at pH 1 by the addition of HCl. Samples were 
incubated at 37 °C for 1 h, finally neutralized with NaOH and analyzed for size on a 
Superdex 75 column with 20 mM Hepes pH 7.4, 0.25 M NaCl as running buffer. 
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2.6.5 Determination of polymer molecular weight by gel permeation 
chromatography (GPC) 
Additional analysis of acid-stable polymers (BM-A1/1, BM-B1/1, LT-OEI-HD) was 
performed using an Agilent 1200 series HPLC system (Agilent Technologies, 
Waldbronn, Germany) equipped with a refractive index detector, a Novema 10-µm 
precolumn and a Novema 300 analytical column (10 µm, 8 x 300 mm) (PSS, Mainz, 
Germany). The mobile phase was maintained in formic acid and sodium chloride (0.1 
% (v/v) HCOOH, 0.1 M NaCl, pH 2.8) at a flow rate of 1 mL/min. Samples were 
dissolved in the mobile phase at a concentration of 6 mg/mL; 10 µl of methanol were 
added to 1 mL of sample as internal standard. Results were evaluated using PSS 
WinGPC Unity software. Molecular weights were measured relative to Pullulan 
molecular weight standards used for preparing a standard calibration curve. 
 
2.6.6 Hydrolysis assays 
Hyrolysis kinetics of the acetal linkage in PEG-A-PEI25K 
The PEG-A-PEI25K conjugate (0.0092 µmol, 0.8 ml) was adjusted to pH 5 by the 
addition of sodium acetate (0.333 M) to a final concentration of 0.2 M total volume 2 
ml and was incubated for 22 h at 37 °C. The reaction was applied to and separated 
on the cation-exchange column and the unbound PEG fractions were pooled and the 
amount of PEG was quantified (78). 
For hydrolysis kinetics measurements compound 9 was dissolved in the respective 
buffer (0.2 M Hepes buffer pH 7.4; 0.2 M Hepes buffer pH 7.0; 0.2 M phosphate 
buffer pH 6.5; 0.2 M phosphate buffer pH 6.0; 0.2 M phosphate buffer pH 5.5; 0.5 M 
NaOAc buffer pH 5.0) at a concentration of 1.5 mg/ml. 
Hyrolysis kinetics of MK and BM linked polymers 
Aliquots of MK-A1/1 or BM-A1/1 were dissolved either in 1 mL 20 mM Hepes buffer 
pH 7.4 containing 0.25 M NaCl or in 1 mL 0.2 M sodium acetate buffer pH 5.0 
containing 0.25 M NaCl. After incubation at 37 °C for different time periods, samples 
were applied to a gel filtration column (Superdex 75) either directly (pH 7.4 samples) 
or after neutralization with sodium hydroxide to stop hydrolysis (pH 5.0 samples). 
SEC was performed as indicated above. For calculation of the degradation rates, the 
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monitored curves were segmented, integrated and the integrals were set into 
relation. 
Hyrolysis kinetics of BAA linked polymers 
For BAA polymer kinetics of acetal hydrolysis was measured by monitoring the UV 
absorption of the emerging hydrolysis product (p-methoxy-benzaldehyde) at 300 nm. 
Therefore, the polymer was diluted with 0.2 M sodium acetate buffer pH 5.0 for the 
pH 5.0 measurements, while 0.2 M Hepes buffer pH 7.4 was used for the pH 7.4 
kinetics. Samples were incubated at 37 °C and absorption was determined on a 
GENESYSTM 10 Series Spectrometer (Thermo Electron Corporation, Pittsford, NY) 
at different time points. 
Hyrolysis kinetics of HD linked polymer 
Hydrolysis of LT-OEI-HD was monitored by 1H NMR analysis as the polymer lacks 
appropriate UV absorbing functions. Therefore the polymer was incubated in D2O at 
pH 7.4 and 37 °C. After different periods of time – up to 14 days – 1H NMR spectra 
were recorded and the decrease of the ester signal was analyzed.  
 
2.6.7 Ethidium bromide (EtBr) exclusion assay 
Aliquots of the respective polymer were added sequentially to a DNA solution (20 
µg/mL) in HBG (Hepes buffered glucose; 20 mM Hepes pH 7.4 plus 5 % w/v 
glucose) containing 400 ng/mL EtBr, and the decrease of fluorescence was 
measured in a Varian Cary Eclipse fluorescence spectrometer (Varian, Mulgrave, 
Australia). EtBr/DNA fluorescence (λex 510 nm and λem 590 nm) was set to 100 % 
prior to addition of polycation. 
 
2.6.8 Formation of polyplexes 
Plasmid DNA (pDNA) was mixed with the polycation at the indicated ratios. In case 
of PEI polyplexes these ratios are given as molar ratios of PEI nitrogen atoms to 
DNA phosphate (N/P); various PEI derivatives were included in the formulation at the 
indicated ratios, as unmodified PEI (PEI22K or PEI25K), targeting conjugate (EGF-
PEI or Tf-PEI) or shielding conjugate (PEG-S-PEI or PEG-A-PEI). In case of 
OEI800- or PEI1.8K-based polymers the ratios are given as cation/pDNA (c/p) ratios 
(w/w). For PEI, c/p 0.78 presents N/P 6. Polycation/DNA polyplexes were prepared 
as described in (75) at final DNA concentrations of 100 µg/mL for biophysical 
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analysis on the zetasizer and of 20 µg/mL for in vitro transfection experiments. 
Briefly, indicated amounts of pDNA and polycations were each diluted in HBG or 
HBS pH 7.4 and mixed rapidly by pipetting. Polyplexes were incubated at room 
temperature for 20 min prior to use. 
 
2.6.9 Particle size and zeta potential 
Particle size and surface charge of polycation/pDNA complexes were measured by 
laser-light scattering using a Malvern Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). For these measurements complexes (preparation in HBG pH 
7.4 as described above) were diluted with the indicated buffer to a final DNA 
concentration of 10 µg/ml (total volume 1 ml): for measurements at physiologic pH 
HBG or 0.5 x HBS of pH 7.4 was used, while for measurements in acidic milieu 20 
mM NaOAc buffer pH 5.0, containing 75 mM NaCl, was added. For kinetics 
measurements these polyplexes dilutions were incubated at 37 °C for the indicated 
time periods. 
 
2.6.10 Cell culture 
Renca-EGFR mouse renal carcinoma cells stably transfected with pLTR-EGFR and 
pSV2neo (kindly provided by Winfried Wels, Frankfurt am Main, Germany) and K562 
suspension cells (ATCC CCL-243) were grown in RPMI-1640 with 4 % Glutamax I 
medium supplemented with 10 % FCS and 1 % antibiotics (streptomycin, penicillin). 
B16F10 murine melanoma cells (kindly provided by I.J. Fidler, Texas Medical 
Center, Houston, TX) and murine neuroblastoma Neuro2A cells (ATCC CCI-131) 
were cultured in DMEM (1 g of glucose/L) supplemented with 10 % FCS (v/v) and 1 
% penicillin/streptomycin (v/v). All cells were grown at 37 °C in 5 % CO2 humidified 
atmosphere. 
 
2.6.11 Luciferase reporter gene expression and metabolic activity of 
transfected cells 
Transfection experiments concerning the acid-labile PEG shielding of EGF- or Tf-
receptor targeted PEI polyplexes were performed on Renca-EGFR or K562 cells. 
Renca-EGFR cells were seeded in 96-well plates with 5 x 103 cells per well 24 h 
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prior to transfection. K562 (2.5 x 105 cells in 0.75 mL) were plated in 24-well plates; 
Transfection polyplexes were added to each well at the amounts of 200 ng pCMVL 
plasmid DNA per well in case of Renca-EGFR cells and 2.5 µg in case of K256 cells. 
After 4 h of incubation at 37 °C the transfection medium was replaced by fresh 
culture medium. Luciferase gene expression was measured after 24 h as described 
(81). Values are given as relative light units (RLU) and represent the luciferase 
activity per 104 (Renca) or 2.5 x 105 (K562) cells. 2 ng of recombinant luciferase 
(Promega, Mannheim, Germany) correspond to 107 light units. 
In vitro transfection experiments with the OEI800- and PEI1.8K-based polymers 
were performed on either B16F10 or Neuro2A cells. Two parallel transfection series 
were carried out in separate well plates (TPP), one for the determination of reporter 
gene expression and one for the determination of metabolic activity. 24 h prior to 
transfection cells were seeded in 96-well plates with a density of 5 × 103 (B16F10) or 
1 × 105 cells (Neuro2A) in 200 µl of culture medium (DMEM supplemented with 1 g 
of glucose/L, 10% FCS (v/v) and 1% penicillin/streptomycin) per well. Immediately 
before transfection, medium was removed from the wells and 100 µl of a dilution of 
transfection complexes (200 ng pDNA/well) in culture medium were added to the 
cells. In case of experiments with bafilomycin A1, bafilomycin A1 (1 mM in DMSO) 
was added to the complex dilutions to give a final concentration of 100 nM, before 
addition to the cells. After 4 h of incubation at 37 °C complex containing medium was 
replaced by 100 µl of fresh medium. Transfection efficiency was evaluated 24 h after 
treatment by measuring luciferase reporter gene expression using a luminometer 
(Lumat LB 9507; Berthold Technologies, Bad Wilbad, Germany) as described 
previously (35). Values are given as relative light units (RLU) and represent the 
luciferase activity per 104 cells. 2 ng of recombinant luciferase (Promega, Mannheim, 
Germany) correspond to 107 light units. 
Relative metabolic activity of cells was determined 24 h after transfection by the 
methylthiazoletetrazolium (MTT)/thiazolyl blue assay as described in (82). Optical 
absorbance was measured at 590 nm (reference wavelength 630 nm) using a micro 
plate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). Metabolic 
activity was expressed relative to the metabolic activity of untreated control cells, 
regarded as 100 %. 
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2.6.12 Enhanced green fluorescent protein (EGFP) gene expression study 
B16F10 cells were seeded 24 h prior to transfection in 24-well plates with a cell 
density of 2 × 104 cells in 1 ml of culture medium (DMEM supplemented with 1 g of 
glucose/L, 10% FCS (v/v) and 1% penicillin/streptomycin) per well. Just prior to 
transfection, medium was removed and replaced by 1 ml of a dilution of the 
transfection complexes (1 µg pEGFP-N1/well) in culture medium. After 4 h of 
incubation at 37 °C the complex containing medium was replaced by 1 ml of fresh 
medium. Finally, after additional 20 h of incubation, the cells were washed with 
phosphate-buffered saline (PBS) and harvested by trypsin treatment. Analysis was 
performed as described in (83) using a CyanADP flow cytometer (DakoCytomation, 
Kopenhagen, Denmark). 1 × 104 gated events were collected per sample; values are 
given as the average of three transfected wells. 
 
2.6.13 In vivo biocompatibility study 
Animal experiments were performed according to National Regulations and were 
approved by the Local Animal Experiments Ethical Committee. Female Balb/c mice 
were purchased from Janvier (Le Genest St Isle, France). Animals were housed in 
individually vented cages; food and water were provided ad libitum. For toxicity 
studies, polymers were dissolved in HBG and injected into the tail vain of the 8-
week-old mice. Thereby the polymers were applied at amounts of 100 or 50 µg/20 g 
mouse, in an injection volume of 250 µl (The polymer amounts are calculated for the 
amount of polycation in the polymers, the PEG content is not included in the mass 
declarations.). At 48 h after polymer treatment, mice were killed and perfusion-fixed 
with formalin solution (4 % paraformaldehyde in phosphate-buffered saline). Main 
organs (livers, kidneys, lungs) were resected and embedded in paraffin. Sections of 
5 µm thickness were cut and stained with hematoxylin-eosin for histological 
investigations. Microscopic pictures were taken with a Framos Infinity 2-3C, CCD-
camera on an Axiovert 200 inverted microscope (Carl Zeiss) using a × 40 LC 
Achroplan objective. 
For determination of the liver-specific blood enzymes alkaline phosphatase (AP) and 
aspartate aminotransferase (AST), blood was collected by heart puncture 
immediately after sacrification using heparinized syringes. Samples were centrifuged 
at 3,000 g for 10 min at 4 °C and the supernatants were collected for plasma 
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analysis. AP and AST were measured using a kinetic UV test from Olympus 
(Olympus Life and Material Science, Hamburg, Germany). 
 
2.6.14 Statistical analysis 
Results are presented as mean ± sd. Data were evaluated by variance analysis 
(ANOVA) using the Duncan test; p-values smaller than 0.05 were considered to be 
significant; 
* p < 0.05, ** p < 0.01, *** p < 0.001.
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3 Results 
 
3.1 pH-sensitive PEGylation of polycations 
 
3.1.1 Synthesis of PEG-A-MAL, a novel pH-sensitive PEGylation reagent 
As shown in Scheme 1A, the initial synthesis of the acetal linker was developed with 
2-methoxyethanol instead of mPEG (see supporting information). This was 
necessary for optimization of the synthesis as well as for the characterization of the 
linker by NMR, as the PEG signal overlaps several signals of the synthesis 
intermediates. The synthesis of the methoxyethanol acetal ME-A-MAL (5) was 
achieved in four reaction steps, each of which was confirmed by NMR analysis.  
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Scheme 1. (A) Synthesis of methoxyethanol acetal ME-A-MAL (5) and (B) of the pH-
sensitive PEGylation reagent PEG-A-MAL (9). 
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In a similar manner the PEG acetal linker was synthesized as shown in Scheme 1B. 
In the first step p-bromobenzaldehyde was reacted with mPEG to generate the 
corresponding acetal (6) with a 97 % yield. Formation of the acetal was confirmed by 
1H NMR, by appearance of a singlet at 5.56 ppm (acetal proton) and the 
disappearance of a singlet at 9.96 ppm (aldehyde proton). The bromo group of 6 was 
then substituted with trimethylsilylethyloxocarbonyl piperazine by the Buchwald 
Hartwig reaction with 2-trimethylsilylethyl piperazine-1-carboxylate. 1H NMR shows 
that the product obtained was a mixture of the piperazine substituted acetal 7 (82 %) 
and the starting material 6 (18 %). The signals proving the existence of 7 appear as 
a singlet at 0.04 ppm belonging to the nine protons of the trimethylsilyl group, a 
multiplet of the methylene function next to the trimethylsilyl group at 0.98-1.03 ppm 
and a triplet from four piperazine protons at 3.13 ppm while the signal of the other 
four piperazine protons is overlapped by the PEG signal. For 6 the acetal proton is 
represented at 5.56 ppm and the aromatic protons at 7.34-7.40, 7.45-7.52ppm. The 
respective signals for 7 are shifted to 5.50 ppm and to 6.87-6.92 and 7.31-7.36 ppm. 
The trimethylsilylethyloxocarbonyl protecting group of 7 was removed by reaction 
with TBAF·3H2O, resulting in a 90 % yield. Subsequent 1H NMR analysis of the 
reaction product 8 showed the de-protection of the amine moiety by the appearance 
of a signal at 2.94-2.99 ppm which corresponds to the four protons at the carbons 
next to the secondary amine. A 3-oxopropyl maleimido function was introduced at 
the deprotected amine by reacting 8 with N-succinimidyl-3-maleimidopropionate, 
resulting in a shift of the 1H NMR signal from 2.94-2.99 ppm to lower field, which 
could not be observed due to the broad overlapping PEG signal. Furthermore a 
singlet appeared at 6.69 ppm, indicating the two methine protons of the maleimido 
group. In addition a multiplet emerged at 2.63-2.70 ppm, corresponding to the two 
protons next to the carboxy group of the new substituent. Product 9, the PEGylation 
reagent PEG-A-MAL used in the subsequent studies, was obtained with a 71 % 
yield. 
To ascertain the pH sensitivity of the linker, hydrolysis of 9 was carried out at pH 5.0, 
5.5, 6.0, 6.5, 7.0 and pH 7.4. The assay was performed at 37 °C and the hydrolysis 
was determined at different time points by measuring the absorbance at 340 nm, the 
main absorbance of the released aldehyde. Half-life continuously decreased with 
decreasing pH. At pH 7.4 the acetal hydrolyzed with a half-life of approximately 1 h, 
while at pH 5 the half-life was less than 3 min. At a pH of 6, which is relevant for PEI 
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containing endosomes (84, 85), PEG-A-MAL degraded with a half-life of less than 10 
min (Figure 4A). The curves in Figure 4B show the hydrolysis rates of PEG-A-MAL 
at defined time points as a function of the pH. For pH 5 at all three time points – 5, 
10 and 15 min – the reagent showed almost complete degradation, while for pH 7.0 
between 96 and 80 % remained intact during the indicated time periods. 
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Figure 4. Time-course of the cleavage of PEG-A-MAL (9) and formation of the 
corresponding aldehyde at 37 °C at different pH values (pH 7.4  , pH 7.0  , pH 
6.5  , pH 6.0  , pH 5.5  , pH 5.0  ) (A). 
Hydrolysis rate of PEG-A-MAL (9) as a function of pH shown for different time 
points at 37 °C (5 min  , 10 min  , 15 min  ) (B). 
Experiments were performed in duplicate. Measurement wavelength: 340 nm. 
 
3.1.2 Reversible PEGylation of various polycations with PEG-A-MAL 
Synthesis of the PEG-A-polycation conjugates was achieved by reacting the 
maleimide moiety of the PEG acetal linker 9 with the previously mercapto-modified 
polycations. Different standard polycations, such as PLL58K, branched and linear 
PEIs (PEI22K, PEI25K) but also the biodegradable LT-OEI-HD could be successfully 
reacted with the linker (Scheme 2). Depending on the reactivity of the different 
polycations used, the PEGylation degree of the resulting PEG-A-polycation 
conjugates slightly varied, thus about 1 to 1.5 SH groups in the thiolated polycation 
were required for 1 PEG-A-MAL linker in the end product. For PEG-A-PEI25K for 
example, about 1.5 SH groups per PEG-A-MAL were necessary. In contrast for 
PEI22K, the SH/PEG-A-MAL ratio was about 1/1, possibly due to a better 
accessibility of the thiols in the linearly structured polycation. The PEG-A-PEI25K 
conjugate described herein in more detail had a PEG/PEI25K molar ratio of 
approximately 3/1, corresponding to approximately 1.5 acetal moieties per PEI25K. 
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Scheme 2. Reversible PEGylation of variable polycations with PEG-A-MAL. 
Thiol functionalized polycations as poly-(L-lysine) (PLL), polyethylenimine (PEI) or 
degradable analogs (LT-OEI-HD) were reacted with a 4-fold excess of the 
PEGylation reagent. Resulting PEG-A-polycation conjugates were purified on a 
Macro-prep High S cation exchange column. 
 
The hydrolytic profile of the PEG-A-polycation conjugates was exemplarily 
determined for PEG-A-PEI25K by measuring the absorbance at 340 nm in a similar 
manner as in case of PEG-A-MAL. Figure 5 shows the time course of hydrolysis of 
the PEG-A-PEI25K conjugate at either pH 7.4 or pH 5.5 at 37 °C. The PEG-A-
PEI25K had a half-life of approximately 3 min at pH 5.5, while the half-life was 2 h at 
pH 7.4. 
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Figure 5. Time-course of the 
cleavage of PEG-A-PEI25K and 
formation of the corresponding 
aromatic aldehyde at pH 7.4 (black 
circles) and pH 5.5 (open circles) at 
37 °C. Experiments were performed 
in duplicates. 
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To investigate the effect of PEG conjugates on the shielding of polyplexes, particle 
size and zeta potential were measured. For comparison: control PLL58K or PEI22K 
particles at N/P 6 without PEG and targeting ligands have a surface charge of about 
30 mV and – in case of PEI22K – form aggregates (81). In preliminary experiments 
with polyplexes composed of either PLL58K plus PEG-A-PLL58K, PEI25K plus PEG-
A-PEI25K or PEI22K plus PEG-A-PEI22K the appropriate ratios of PEGylated/non-
PEGylated polycation were determined. 20-30 % (w/w PEI) (depending on the 
PEGylation degree and the type of the polycation) of the polycation being PEGylated 
turned out to be the optimal composition to achieve complete polyplex shielding at 
physiologic pH and quick deshielding at pH 5.0. In the next step, targeting ligands 
were includes into the polyplexes. Here, PLL polyplexes were not analyzed further, 
as PEIs are the more interesting polymers regarding gene transfer. Table 1 shows 
particle sizes and zeta potential of polyplexes containing a targeting conjugate (EGF-
PEI or Tf-PEI) with and without PEG shield (PEG-S-PEI25K or PEG-A-PEI25K) at 
pH 7.4 and 37 °C. All PEGylated polyplexes remained shielded and stable in size for 
2 h, whereas non-PEGylated polyplexes formed aggregates. Figure 6 shows the 
time-dependent changes of PEG-A-PEI25K shielded polyplexes incubated at either 
pH 5.0 or pH 7.4 and 37 °C. At pH 5.0 the PEG-A-PEI25K shielded polyplexes 
formed aggregates at the 0.5 h time point, indicating PEG removal under these 
conditions. In contrast, at pH 7.4 polyplexes were stable in size and retained low 
surface charge for the whole 2 h time period. Even after 4 h at pH 7.4 – representing 
the incubation time of cells with polyplexes – particles remained shielded (data not 
shown). Different targeting conjugates (EGF in Fig. 3A, B; Tf in Fig. 3C, D) did not 
significantly alter the biophysical properties.  
Polyplexes containing the non-reversible conjugate PEG-S-PEI25K instead of PEG-
A-PERI25K did not change in size and remained shielded at both pH values (Table 1 
and data not shown).  
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3,12033,021120% PEG-A-PEI25K, 10% Tf-PEG-PEI
3,22233,222420% PEG-A-PEI25K, 10% EGF-PEG-PEI
3,21693,220420% PEG-A-PEI25K, 10% PEI25K
2,81792,919820% PEG-S-PEI25K, 10% Tf-PEG-PEI
2,72513,023220% PEG-S-PEI25K, 10% EGF-PEG-PEI
2,41772,119620% PEG-S-PEI25K, 10% PEI25K
13,7aggregates*18,2aggregates*20% PEI25K, 10% Tf-PEG-PEI
14,0aggregates*18,826720% PEI25K, 10% EGF-PEG-PEI
zeta [mV]size [nm]zeta [mV]size [nm]70% PEI22K with:
2 h0 hFormulation: 
 
 
Table 1. Particle size and zeta potential of various polyplex formulations of N/P 6, 
at the 0 and 2 h time point, pH 7.4. Each value represents the mean of at least three 
readings. * The term “aggregates” refers to particles over 1 µm in size. 
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Figure 6. Time-course of the zeta potential (A, C) or particle size (B, D) of 
polyplexes consisting of 70 % (w/w; PEI) PEI22K, 20 % PEG-A-PEI25K and 10 % 
EGF-PEI (A, B) or 10 % Tf-PEI (C, D) at pH 7.4 (closed circles) and at pH 5.0 (open 
circles) at 37 °C. Each point represents the mean ± s.d. of three experiments. 
* particles over 1 µm in size. 
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The transfection efficiency of the various polyplex formulations was tested using a 
luciferase gene expressing plasmid. EGF containing polyplexes (83, 86) were 
applied on Renca-EGFR cells and Tf containing polyplexes (74, 81) on K562 cells. 
To avoid extracellular deshielding transfection medium was sucked off after 4 hours 
of incubation and replaced by fresh culture medium. All targeted, reversibly shielded 
polyplex formulations had greater gene transfer activity as compared to the 
analogous stably shielded formulations (see Figure 7A for Renca-EGFR and Figure 
7B for K562). The effect of pH-sensitive PEGylation was most pronounced at a 
molar PEI nitrogen/DNA phosphate (N/P) ratio of 3 in Renca-EGFR, with a 14-fold 
enhanced gene expression compared to non-sensitive PEGylation (Figure 7A). 
Analog, for K562 cells the effect of pH-sensitive PEGylation was most pronounced at 
a molar N/P ratio of 6 resulting in 8-fold enhancement of gene expression (Figure 
7B). As polyplexes remained shielded within the incubation time, the higher 
transfection efficiency of reversibly shielded compared to stably shielded polyplexes 
must be due to intracellular deshielding and not to an increased uptake because of 
extracellular deshielding. 
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Figure 7. Luciferase gene expression by EGF-receptor-targeted polyplexes on 
Renca-EGFR cells (A) and by transferrin-receptor-targeted polyplexes on K562 
cells (B).   
Polyplexes were composed of 70 % PEI22K, 10 % targeting ligand (EGF-PEI or Tf-
PEI respectively) and 20 % of either PEI25K (nonshielded polyplexes, white bars), a 
stable PEG-PEI25K conjugate (stably shielded polyplexes, black bars) or PEG-A-
PEI25K (reversily shielded polyplexes, gray bars). Each bar represents the mean ± 
sd of three individual experiments, each performed in triplicate. 
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3.2 pH-sensitive biodegradable cationic carriers 
 
3.2.1 Acid-degradable bisacrylate acetal (BAA) and maleimido ketal (MK) 
polymers and acid-insensitive HD and BM control polymers 
 
3.2.1.1 Polymer syntheses and structural analysis 
The control polymer LT-OEI-HD (1,6-hexanediol diacrylate linked OEI800 
synthesized at low temperature (LT), i.e. 22 °C) was synthesized as described by 
Kloeckner et al. (79). All polymers were generated by reacting OEI800 via its amine 
functions with bifunctional linkers in a Michael addition (Scheme 3). In case of 
maleimido-functionalized linkers (MK and BM) reaction time was 22 hours, while for 
acrylate linkers different reaction times were chosen: 4 days in case of LT-OEI-HD 
(HD linker is not as amenable to aminolysis as BAA linker), 45 min, 1.5 days or 3 
days in case of BAA polymers. The Michael addition between BAA linker and 
OEI800 is complete after 45 minutes, therefore an elongation of the reaction time 
causes only higher extents of aminolysis. Polymers synthesized from maleimido 
linkers (BM and MK) in contrast, do not show this side-reaction. Therefore, changes 
in the reaction time do not influence the chemical structure of the products here, as it 
is the case for the acrylate linked polymers. All syntheses were carried out in 
anhydrous DMSO at room temperature (22 °C) to prevent degradation of the acetal 
and ester functions present in the linker moieties (79). The nomenclature of the novel 
polymers (i.e. MK-A1/1, BM-A1/1, BAA-1/1-3d, -2/1-3d, …) is composed as follows: 
first, the applied linker (MK, BM, …) is specified, in case of application of different 
monomeric units followed by an abbreviation thereof (A for OEI800, B for PEI1.8K); 
secondly, the linker/OEI molar input ratio (1/1, …) is noted; in case of BAA polymers 
where reactions were carried out over different periods of time, the reaction time is 
mentioned at the end. 
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Scheme 3. Syntheses of the oligoethylenimine based polymers: acid-
degradable acetal-linked OEI-MK and OEI-BAA polymers and acid-nonsensitive 
control polymers OEI-BM and LT-OEI-HD. a: acid-labile MK-linker; b: acid-stable 
BM-linker; c: acid-labile BAA-linker; d: acid-nonsensitive HD-linker. (The more 
general names “OEI-MK”, “OEI-BAA”, etc. used here stand representatively for the 
whole groups of MK-, BAA or BM-linked polymers)  
 
 
 
Purification of the products from the solvent and from unreacted starting material 
was achieved by dialysis at 4 °C using a 3.5 kDa molecular mass cut off membrane. 
After freeze-drying BM-A1/1 and MK-A1/1 were obtained as red solid in yields of 48 
% and 40 %, respectively. BAA polymers and LT-OEI-HD gave colorless solids in 40 
% (BAA-1/1-3d), 50 % (BAA-2/1-3d), 56 % (BAA-1/1-1.5d), 70 % (BAA-1/1-45m), 58 
% (BAA-1/1-45m-hc) and 65 % (LT-OEI-HD) yield. Polymers were then analyzed by 
1H NMR to investigate their chemical structure (OEI to linker ratio) and to confirm the 
preservation of the labile acetal functions during synthesis and purification. For BM-
A1/1 a linker to OEI ratio of 1.3/1 was found. For MK-A1/1 the linker to ketal to OEI 
ratio was 1.03/0.93/1, indicating a ≤10 % hydrolysis of ketal groups in the product 
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during workup. LT-OEI-HD had a HD to OEI ratio of 1.25/1, with 77 % of esters 
remaining intact. The slightly reduced ester content is not triggered by hydrolysis, but 
can be ascribed to low-level partial exchange reaction, i.e. aminolysis by OEI amines 
during the synthesis in water-free DMSO, and does not negatively affect the polymer 
size (79). For BAA polymers which are more sensitive towards aminolysis (Scheme 
4), the content of intact diester in the linker molecules was 26 % for BAA-1/1-3d and 
BAA-2/1-3d; if the reaction was finished already after 1.5 days (BAA-1/1-1.5d) a 
diester content of 40 % was maintained. Reduction of the reaction time to only 45 
min increased the diester content in the linker to 75 % (BAA-1/1-45min) and 60 % 
(BAA-1.25/1-45min-hc).  
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Scheme 4. Aminolysis of BAA polymers: amine functions of OEI800 moieties 
react intra- or intermolecularly with the ester fuctions of the polymer, resulting in 
stable amide bonds. 
 
For the better understanding of the amide formation during the synthesis process 
(Scheme 4), the synthesis of BAA-1/1 has been additionally performed in DMSO-d6 
as solvent, so that the reaction could be followed by 1H NMR. By analyzing the 
signal of the acetal protons (5.6 - 5.5 ppm) the ratios of dieester/monoester/diol 
could be investigated (Figure 8A). The process of aminolysis of the ester bonds over 
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time, and therefore the dependence of diester content from the reaction time is 
illustrated in Figure 8B. 
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Figure 8. Structural analysis of BAA-1/1 during polymer synthesis at 22 °C in 
DMSO-d6: 1H NMR spectra (A) were recorded at different time points (shown here: 
reaction time 48 h) during the reaction and the degree of aminolysis was calculated 
on the basis of the acetal signal (5.6 - 5.5 ppm). This signal shows three different 
chemical shifts: for the intact diester it is located at 5.57 ppm (a), for the monoester 
(aminolysis on one side of the linker) it is shifted slightly to the higher field and 
appears at 5.54 ppm (b), while in case of the diol (aminolysis on both linker sides) it 
appears as a peak at 5.50 ppm (c). 
Diagram of the 1H NMR based kinetics of BAA aminolysis over 28 days (B). 
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Infrared analysis of BAA-1/1-45min, BAA-1/1-1.5d and BAA-2/1-3d additionally 
confirmed the presence of amides (amide bond: 1645 cm-1) in the polymers as well 
as the increase of amide and decrease of ester bonds (ester bond: 1732 cm-1) with 
the elongation of reaction time.  
An estimate of molecular weight (m.w.) of the polymers was obtained by size 
exclusion chromatography (Figure 9) using Superdex 75 for the separation in the 
low m.w. range and Superdex 200 one for separation in the high m.w. range. As 
running buffer 20 mM Hepes containing 0.25 M NaCl, adjusted at pH 7.4 was used. 
At this pH, acid-labile functions as well as esters are sufficiently stable during the 
run. Calibration with standard polymers of known m.w. and of comparable chemical 
structure, OEI800, PEI2K, PEI10K, PEI25K and PEI50K, was performed. Figure 9 
shows the elution profiles of polymers compared with the elution times of the 
standards. For all polymers a broad size distribution was found. In case of BM-A1/1 
and MK-A1/1 the main peak maximum in the elution profiles was located at about 12 
minutes on Superdex 75 (Figure 9A) and 20 minutes on Superdex 200 (Figure 9B), 
indicating a m.w. of about 10 kDa or slightly less. While this main maximum was the 
same for the both polymers, the average size of BM-A1/1 was slightly higher than 
that of MK-A1/1: in MK-A1/1 low m.w. fractions are present to a higher extent than in 
BM-A1/1.  
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Figure 9. Investigation of polymer molecular weight by size exclusion 
chromatography (SEC). Elution profiles of MK-A1/1 and BM-A1/1 on a Superdex 75 
column (A) for fractionation in the low m.w. range, and on Superdex 200 for 
separation in the high m. w. range (B). Elution profiles of BAA polymers and LT-OEI-
HD on Superdex 75 (C). Peaks at the very right side of the diagrams (marked by 
shaded boxes) were induced by salt and do not refer to the samples. 
 
When analyzed on Superdex 200, which separates in the higher m.w. range, another 
smaller maximum can be found for BM-A1/1 at about 12 minutes – thus  lying slightly 
below the 50 kDa standard (10.5 min) (Figure 9B and 10A lower panel). Additional 
analysis of BM-A1/1 by gel permeation chromatography on a Novema 300 column 
(Figure 10A, upper panel) showed a maximum in the lower m.w. range at 7 kDa (a) 
and a second one in the higher m.w. range at 40 kDa (b). These results are well 
comparable to those obtained from Superdex 200. The average values calculated for 
BM-A1/1 from the Novema analysis resulted in Mn = 8.5 kDa and Mw = 36 kDa with 
a polydispersity of 4.2. 
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c* c**
 
Figure 10. Investigation of polymer molecular weight by GPC and SEC. 
Comparison of results obtained on a Novema 300 column with those received 
on Superdex columns. 
(A) BM-A1/1: upper panel, Novema 300 (a: 7 kDa; b: 40 kDa); lower panel, Superdex 
200 (a*: 20 min, corresponding to 8-10 kDa; b*: 12 min, corresponding to about 40 
kDa) 
(B) LT-OEI-HD: upper panel, Novema 300 (c : 8 kDa); lower panel, Superdex 200 
(c*: 19 min, corresponding to 8-9 kDa); Superdex 75 (c**: 10 min, corresponding to 
10 kDa) 
 
 
18.5 mL (Sup. 75)800 Da - 9 kDa2-3 kDa
BAA-1.25/1-
45min-hc
18.5 mL (Sup. 75)800 Da - 8 kDa2-3 kDaBAA-1/1-45min
18.5 mL (Sup. 75)800 Da - 10 kDa2-3 kDaBAA-1/1-1.5d
18.5 mL (Sup. 75)800 Da - 10 kDa2-3 kDaBAA-1/1-3d
75);
12, 14, 17mL (Sup.8-10 kDa
20 mL (Sup. 200);800 Da - 10 kDa4 kDa,BAA-2/1-3d
4.321 kDa4.9 kDa10.1 mL8 kDa20 mL (Sup. 200)800 Da - 50 kDa8-10 kDaLT-OEI-HD
20 mL (Sup. 200)800 Da - 50 kDa8-10 kDaMK-A1/1
40 kDa20 mL (Sup. 200)40 kDa
4.236 kDa8.5 kDa10.3 mL7 kDa12 mL (Sup. 200),800 Da - >50 kDa8-10 kDa,BM-A1/1
PDIMwMnVpMpVpm.w. rangeMp
GPCSECPolymer
 
 
Table 2. Overview over the key data obtained by SEC and GPC. Polymer size 
characterization by SEC, and in case of acid-stable polymers also by GPC: m.w. at 
peak maximum (Mp), m.w. ranges, elution volume at peak maximum (Vp), molecular 
weight by number (Mn) and by weight (Mw), polydispersity index (PDI). For SEC 
experiments Vp was calculated from the elution times in consideration of the flow 
rate (1 mL/min). 
 
A broad polydispersity was also found for BAA polymers and LT-OEI-HD. Analysis 
on Superdex columns showed that these polymers were smaller in size compared to 
MK-A1/1 and BM-A1/1. Among the acrylate linked polycations LT-OEI-HD was the 
 - 55 - 
3 Results    
 
 
largest with a peak maximum slightly below the 10 kDa standard (Figure 10B, lower 
panel). As LT-OEI-HD is acid-stable it was additionally analyzed on a Novema 300 
column (Figure 10B, upper panel). Here the peak maximum appeared at a molar 
mass of about 8 kDa (c), which is in good accordance with the Superdex 200 and 75 
results, where the maxima in the elution profiles were located at 19 (c*) or 10 
minutes (c**) respectively, indicating m.w. of 10 or slightly below 10 kDa (for elution 
profiles of standards see also Figure 9B and C). For LT-OEI-HD the values 
calculated from Novema analysis were Mn = 4.9 kDa and Mw = 21 kDa with a 
polydispersity of 4.3. 
BAA polymers showed SEC peak maxima in the range of 2-3 kDa and size 
distributions reaching from the monomer up to 8-10 kDa. Thereby, a differentiation 
between polymers with higher and lower linker content was possible: compared to 
the BAA-1/1 polymers, the BAA-2/1-3d elution profile is slightly shifted to the higher 
m.w. fractions (Figure 9C). 
Based on the good correlation of SEC and GPC data and the fact that the 
established GPC method required the use of pH 2.8 mobile phase, m.w. distribution 
of the pH-labile polymers were analyzed by SEC only. A detailed overview over the 
data is given in Table 2. 
 
3.2.1.2 Chemical and biophysical properties 
Degradation study of MK-A1/1 and BAA polymers. To evaluate the pH 
dependency of the hydrolysis of the acid-labile linkers in MK-A1/1 and BAA 
polymers, degradation kinetics were measured in incubations at body temperature 
(37 °C) at physiological pH 7.4 as well as at pH 5.0 (Figure 11). The half-life of MK-
A1/1 was about 5 h at pH 7.4 (Figure 11A), while at pH 5.0 the polymer hydrolysis 
was almost complete (98 %) after 15 min. In contrast, control polymer BM-A1/1 was 
stable even after 20 h of incubation at pH 5.0 and 37 °C (data not shown). 
Degradation of the acetal function in BAA polymers was analyzed in more detail by 
measuring the increase of UV-absorbance of the released aromatic benzaldehyde. 
Here, at pH 5.0 hydrolysis proceeded with a half-life of about 3 minutes and was 
complete in less than 30 min (Figure 11B) while at pH 7.4 the half-life was about 3 
½ hours (Figure 11C). The slower hydrolysis of the ester bonds (see below) is not 
detectable in this assay.   
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Figure 11. Hydrolysis kinetics of acid-labile polymers at 37 °C. Grey arrows 
mark the half-lives of the polymers. Degradation of MK-A1/1 at physiological pH, 
values calculated from HPLC data (Superdex 75; AUC at different time points after 
incubation) (A). Hydrolysis kinetics of BAA polymers at pH 5.0 (B) and pH 7.4 (C), 37 
°C. UV absorbance (300 nm) of the arising hydrolysis product was measured at 
indicated time points. Each point represents the mean ± sd of three experiments. 
 
 
Dependent on their different acetal and amide contents BAA polymers undergo acid 
catalized hydrolysis to varying extents, which is reflected in hydrolysis end-products 
of different sizes. In a hydrolysis study by SEC (Superdex 75), the degree of this pH 
dependent degradation was investigated. BAA-1/1-45min, the polymer with the 
highest diester – and thus acetal linker – content, degraded completely into 
 - 57 - 
3 Results    
 
 
monomers besides a fraction of remaining dimers. BAA-1/1-1.5d which possesses 
less acetal linkers showed similar results, but here the degradation products were 
shifted more to the dimers compared to the 45min-polymer. Additionally a marginal 
amount of oligomers remained. BAA-2/1-3d, in contrast showed considerable 
amounts of remaining oligomers after acid treatment. Even despite the higher amide 
content of this polymer hydrolysis still took place, especially in the high m.w. range of 
the polymer, indicated by the flattening of the elution profile in this area. 
Degradation of ester bonds was analyzed by 1H-NMR using the ester-bond 
containing control polymer LT-OEI-HD at pH 7.4, 37 °C. The half-life was found to be 
2 days. Under acidic conditions the ester-based polymers would hydrolyze 
significantly slower, as reported by Kloeckner et al. (79). 
 
DNA-binding assay. All polymers were analyzed for their DNA binding affinity by 
ethidium bromide (EtBr) exclusion assay in HBG (Figure 12). The assay revealed 
that the presence of MK or BM linker does not hamper DNA binding. In contrast 
these polymers bound to DNA slightly stronger than native OEI800. For BAA 
polymers the binding capacity was slightly reduced compared to OEI800; for LT-OEI-
HD this was the case only at low c/p ratios, while with increasing c/p DNA binding 
became stronger than for OEI800. 
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Figure 12. DNA-binding affinity of OEI800 and OEI800 based polymers 
determined by ethidium bromide exclusion assay in HBG pH 7.4. The diagram 
shows the influence of the different linkers on DNA condensing ability of the 
polymers. For BAA polymers only BAA-1/1-3d and BAA-2/1-3d are shown. The 
curves of the three other BAA polymers were according. Each point represents the 
mean ± sd of three experiments. 
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Particle size and zeta potential. To further characterize the polymers with regard to 
their use as gene vectors, complexes with pDNA were formed at different c/p ratios. 
These polyplexes were analyzed for their size and surface charge. Additionally, the 
influence of ionic strength on particle stability was investigated. In HBG polymers 
formed polyplexes of small size (BM-A1/1, MK-A1/1: 130 - 200 nm; LT-OEI-HD, BAA 
polymers: 150 – 300 nm) and positive surface charge (23 - 30 mV) at c/p ratios of 1 
and more (Figure 13), with the exception of BAA-1/1-3d where polyplexes 
aggregated with time. For c/p ratios of 0.5 or 0.25 surface charges of polyplexes 
became lower or even negative and also for the other polymers particles tended to 
aggregate. Upon the addition of salt (HBS), aggregation of particles occurred in case 
of polymers with weaker DNA binding ability, i.e. BAA polymers (all c/p ratios tested) 
and LT-OEI-HD (for c/p ratios of 1 or less). 
 
 
 
Figure 13. 
Size and surface charge 
of polyplexes made from 
MK-A1/1, BM-A1/1, BAA-
2/1-3d and LT-OEI-HD at 
different c/p ratios (in 
HBG, pH 7.4). All 
polymers formed small 
particles with positive 
surface charge from c/p 
0.5 or 1.0 (LT-OEI-HD) on. 
Experiments were 
performed in triplicate, 
each point represents the 
mean ± sd. 
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3.2.1.3 In vitro luciferase reporter gene expression and metabolic activity of 
transfected cells 
In order to investigate the influence of polymer acid degradability on transfection 
efficiency and cytotoxicity, B16F10 (Figure 14) and Neuro2A cells (Figure 15) were 
transfected with pCMVLuc reporter gene polyplexes prepared in HBG with the acid-
labile polycations or their acid-insensitive counterparts at different c/p ratios. Linear 
PEI of 22 kDa (PEI22K) previously established as our golden standard was used for 
comparison at its optimal c/p ratio (c/p 0.78,  corresponding to N/P 6) (64). 
For B16F10 cells, the maximum transfection efficiency of both degradable MK-A1/1 
and its stable analog BM-A1/1 reached values of about 1 log unit below the golden 
standard PEI22K applied at c/p 0.78 (Figure 14A). For maximum efficiency, higher 
c/p ratios (5 and more) of MK-A1/1 were required than for BM-A1/1 (optimal 
transfection at a c/p ratio of 2.5). For BM-A1/1 further increase in c/p resulted in a 
reduction of transfection efficiency. This can be explained by significant cytotoxicity 
(Figure 14B) caused by BM-A1/1 at c/p 5 and higher. In contrast, no cytotoxicity was 
observed for pH-labile MK-A1/1 up to c/p 7.5. Consequently, at high c/p ratios the 
acid-labile polymer MK-A1/1 became superior. The starting material OEI800 shows 
no cytotoxicity but also no transfection efficiency, independent from the c/p ratio. The 
golden standard PEI22K shows only moderate cytotoxicity at optimal c/p ratio of 
0.78, but very strong toxicity at higher c/p ratios. Thus, relative metabolic viability of 
B16F10 cells transfected with PEI22K decreased to less than 50 % for c/p 2 and to 
less than 40 % for c/p 4 as shown by Russ et al., (64) in their supplementary 
information.  
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Figure 14. In vitro transfection efficiency (luciferase assay, A, C, E) and 
metabolic activity (MTT assay, B, D, F) in B16F10 cells. Cells were treated with 
polyplexes of MK-A1/1 and BM-A1/1 in comparison to OEI800 and PEI22K (A, B), or 
with BAA and LT-OEI-HD (C, D). Diagrams E and F show the influence of acetal 
linker content on transfection efficiency and toxicity of BAA polymers. 
Each bar represents the mean ± sd of three individual experiments, each performed 
in triplicate. # in figure A: OEI800 < 103 RLU for all c/p ratios tested. 
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The BAA polymers and its acetal-free ester analog LT-OEI-HD (Figure 14C, D) were 
also evaluated on B16F10 cells. Here, BAA-1/1-3d was the most promising polymer, 
with an optimal transfection efficiency (at c/p of 7.5) significantly exceeding even 
PEI22K (Figure 14C). The acetal-free control polymer LT-OEI-HD could not reach 
the transfection levels of BAA-1/1-3d and BAA-2/1-3d. Although the ester-based 
degradable polymer LT-OEI-HD is far less cytotoxic than PEI22K, it showed 
considerable toxicity at c/p ≥ 5. The acetal- and ester-containing BAA counterparts 
showed the best biocompatibility among the four polymers tested (Figure 14D). 
Again it was especially at the higher c/p ratios (5.0, 7.5), where the benefit of the 
BAA polymers was clearly visible, not only in terms of improved compatibility but also 
regarding superior gene transfer efficiency. 
To investigate the influence of diester-, and therefore also acetal-content in BAA 
polymers on the transfection efficiency/cytotoxity profiles, several BAA polymers that 
differ in their linker content were compared. BAA-2/1-3d, BAA-1/1-1.5d, BAA-1/1-
45min and BAA-1/1-45min-hc were chosen, as they provide polyplexes of 
comparable size and surface charge. To see significant toxic effects, it was 
necessary to increase the c/p ratios in this experiment. A clear relationship between 
the amount of acid degradable linker in the polymer and its cytotoxicity could be 
found: although exhibiting better biocompatibility than acetal-free LT-OEI-HD (Figure 
14D), BAA-2/1-3d – the polymer with the poorest degradability among the BAAs – 
became toxic at higher c/p ratios. This was not the case for polymers with higher 
acetal content (BAA-1/1-1.5d and the two 45min variants), where no toxicity occurred 
at all, even at the highest c/p ratio tested (Figure 14F). Concerning transfection 
efficiency (Figure 14E), the polymers with the lowest toxicity showed also the lowest 
transfection levels. While clearly superior to OEI800, BAA-1/1-45min and BAA-1/1-
45min-hc could not reach the efficiency of BAA-2/1-3d or BAA-1/1-1.5d. Thereby, 
BAA-1/1-1.5 was inferior to BAA-2/1-3d at low c/p ratios but became almost equal at 
higher concentrations, while still being completely non-toxic. 
Transfections were also carried out with Neuro2A cells as a second cell line. In this 
cell line gene transfer efficiencies of all polyplexes (including also the standard 
PEI22K) prepared in HBG buffer were low (Figure 15A, solid bars). In contrast, 
transfection efficiency was improved for several polymers if formulations were 
generated in salt-containing HBS buffer (Figure 15A, striped bars). All BAA 
polymers (including also those not shown in figure 7) and PEI22K responded to this 
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procedure with strongly (approximately 100-fold) elevated transfection levels. 
Cytotoxicity (Figure 15B) was not influenced remarkably by the presence of salt, 
except for PEI22K where metabolic activity of treated cells decreased by 20 %. 
Interestingly, HBS had only little influence on the transfection efficiency of LT-OEI-
HD and no influence on MK-A1/1 and BM-A1/1 polyplexes (data not shown). 
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Figure 15. Influence of ionic strength (solid bars: salt free HBG; striped bars: 150 
mM NaCl containing HBS) on the in vitro transfection efficiency (luciferase assay, 
A) and toxicity (MTT assay, B) in Neuro2A cells, a cell line sensitive towards 
particle size. Just like PEI22K, also BAA polyplexes are influenced by the addition of 
salt, which leads to particle growth and therefore increased transfection efficiency.  
Each bar represents the mean ± sd of three individual experiments, each performed 
in triplicate. 
 
 
To get some insight into intracellular behaviour and transfection characteristics of 
BAA and MK polymers, transfection experiments were additionally performed with 
representative polymers using bafilomycin A1, a proton pump inhibitor. It is known 
that, by inhibiting the endosomal acidification, this reagent decreases transfection 
efficiency of polymers with high buffering capacity like PEI (49). In contrast, it has no 
significant influence on transfection efficiencies of polymers lacking this property (for 
example PLL) (87). For this study B16F10 cells were transfected either in presence 
or absence of bafilomycin A1 with MK-A1/1, BAA-2/1-3d or standard PEI22K 
polyplexes. While prevention of endosomal acidification had no significant effect on 
transfection with MK-A1/1 polyplexes, transfections performed with BAA-2/1-3d 
complexes were seriously influenced. As it is known for PEI22K, which in this 
experiment responded to the bafilomycin treatment by a 30-fold decrease in 
transfection efficiency, a remarkable decrease could also be observed for the BAA 
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polymer (Figure 16). For none of the polymers tested the cell viability was affected 
significantly by bafilomycin.  
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Figure 16. Influence of bafilomycin A1 on transfection efficiency of MK or BAA 
polymers in B16F10 cells. PEI22K was applied at optimal N/P ratio of 6. The bars 
represent the mean of three independent experiments, each performed in triplicate. 
(-) indicates transfection in absence of bafilomycin A1, (+) stand for the presence of 
bafilomycin A1, 100 nM. 
 
3.2.1.4 In vivo biocompatibility studies 
As the acid degradable polymers showed promising results concerning 
biocompatibility in vitro, we decided to examine their in vivo toxicity in the next step. 
Therefor different amounts of selected plain polymers (BAA-2/1-3d, MK-A1/1 or 
stable controls) were administered to 8-weeks old female Balb/c mice via tail vain 
injection. Acetal comprising polymers were well tolerated by the mice at amounts of 
50 µg/20 g mouse, and no changes in liver tissue were detectable (Figure 17, upper 
two pictures on the left). Doubling the polymer amount to 100 µg/20 g mouse was 
still well tolerated for BAA-2/1-3d and no pathological alterations in the analyzed liver 
tissue were found; for MK-A1/1 this was also the case for two out of three mice, 
while one of the mice showed first slight signs of developing a fatty liver at the 100 
µg dose. In contrast, stable BM-A1/1 and LT-OEI-HD polymers caused fatty livers 
already at 50 µg/20 g mouse (Figure 17, upper two pictures on the right) and the 
100 µg dosage was lethal in case of BM-A1/1. For control polymer PEI25K the 
dosage had to be even reduced to 25 µg/20 g mouse, as all three animals died, 
 - 64 - 
3 Results    
 
 
when treated with 50 µg. With the 25 µg PEI25K injection hepatocytes lost their 
normal shape indicating necrotic changes (Figure 17). 
 
 
 
Figure 17. In vivo study on toxicity of the free polymers in Balb/c mice. Histological 
examination on liver tissue (hematoxylin-eosin staining) 48 h after i.v. administration 
of indicated amounts of free polymer per 20 g mouse. Application of 50 µg of acid-
labile polymers MK-A1/1 and BAA-2/1 induced no histopathological changes in the 
liver compared to HBG treated control animals. In contrast the same dosage of acid-
stable BM-A1/1 and LT-OEI-HD polymers resulted in the development of fatty livers 
(black arrows indicate lipid droplets in hepatocytes after BM-A1/1 and LT-OEI-HD 
treatment). Mice treated with 25 µg of PEI25K even showed necrotic changes in liver 
tissue, which can be seen by the impaired morphology of hepatocytes in the lower 
right picture. 
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3.3 Further optimization of OEI-MK polymer as gene carrier 
The degradable MK and BAA polymers described below show an improved toxicity 
profile compared to their acid-stable counterparts and their transfection efficiency is 
promising; however, transfection properties might be improved further. Thus, the 
acid-degradable MK-polymer was chosen as an auspicious starting point for the 
development of degradable polymers with enhanced transfection efficiency. For the 
change and optimization of the polymer`s physicochemical properties, attention was 
turned on four aspects: 
Polymer size – as already mentioned, it is well known that an increased molecular 
weight often comes along with enhanced transfection efficiency of polymers (33, 58, 
59). Further, low polydispersity indices (PDI) are preferred over widespread size 
distributions, as characteristics of polymers with low PDI are better defined. Both 
parameters can be improved for MK-A1/1.  
Amine density – beside the molecular mass also the amine density of a polycation 
has an influence on its gene transfer properties. High amine densities, as found for 
example in PEI, are associated with a high buffering capacity, facilitating endosomal 
release (58) and leading to high transfection efficiency.  
Hydrophilic shielding – the introduction of neutral hydrophilic PEG-chains into gene 
vectors does not only reduce vector toxicity but – in certain cases – can also improve 
the gene transfer efficiency (88-90). 
Hydrophobicity – viruses have been shown to utilize hydrophobic, membrane lytic 
domains to induce endosomal release (24). Equipping polymers with hydrophobic 
molecules could therefore also help to facilitate their endosomal release. 
 
3.3.1 Polymers with increased size and amine density 
3.3.1.1 Increased molecular weight: MK-A1/1-Fr.I, MK-A1.2/1, MK-A1.5/1 
a) Polymer syntheses and analysis of their biophysical properties 
As described above, acid-degradable MK-A1/1 polymer is synthesized by reacting 
OEI800 in a 1/1 ratio with the MK-linker, followed by dialysis using a 3.5 kDa cut off 
membrane. In order to obtain polymers with higher m.w., the 1/1 linker/OEI800 input 
ratio as well as the dialysis cut off were increased. Raising the ratio up to 1.2/1 or 
1.5/1 resulted in products containing 1.05 or 1.23 linkers per OEI800 respectively; for 
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comparison: MK-A1/1 contained only 0.93 linkers per OEI. This, combined with the 
use of a 6-8 kDa m.w. cut off dialysis membrane for purification, yielded MK-A1.2/1 
(red solid, 51 % yield) and MK-A1.5/1 (red solid, 60 % yield) as polymers with 
enhanced average molecular mass compared to MK-A1/1. The increase in m.w. was 
attested by SEC using Superdex 75 material for the investigation of the low m.w. 
range and Superdex 200 for separations in the high m.w. range. On Superdex 75 a 
decrease in the low m.w. fractions (oligomers of about 5 kDa and less) was detected 
for MK-A1.2/1 and MK-A1.5/1 compared to MK-A1/1 (Figure 18), while the elution 
profiles on the Superdex 200 column showed an increase in the high m.w. range 
(polymers with m.w. of 25 – 50 kDa) for MK-A1.2/1 and 1.5/1 (data not shown). SEC 
also revealed that all polymers possessed a high polydispersity and residual OEI800 
monomers were still present in the dialyzed products. Thus, another approach 
towards higher average m.w. – and ideally also towards a lower polydispersity – was 
the fractionation of MK-A1/1. Therefor the polymer was separated on a Superdex 75 
column into three fractions, starting with MK-A1/1-Fr.I (Figure 18). This fraction 
comprised the polymer-portion eluting between minute 9 and 15, with the highest 
m.w. parts reaching sizes of about 50 kDa; mono- and oligomers up to about 5 kDa 
were removed. This fraction I was followed by MK-A1/1-Fr.II, which ranged from 
minute 16 to 20 and contained oligomers of about 2-5 kDa in size. Finally MK-A1/1-
Fr.III was collected, containing monomers eluting after 21 minutes and later. Polymer 
concentrations in the collected fractions were determined by copper complex assay. 
 
 
12 19      21 Time [min]
PEI: 10K 2K     800 m.w. [Da]
Fr.I
MK-A1/1
MK-A1.2/1
MK-A1.5/1
 
 
Figure 18. Polymer molecular weight characterization and fractionation via 
SEC: elution profiles of MK-A1/1 (black line), MK-A1.2/1 (dark grey line), MK-A1.5/1 
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(light grey line) on a Superdex 75 column. Decrease of low molecular weight 
fractions in MK-A1.2/1 and MK-A1.5/1 is marked by the white arrow.  
Numbers on the scale below the curves indicate the elution times and sizes of 
standard PEI polymers with known molecular weight. 
  
 
 
b) In vitro transfection results (luciferase reporter gene expression) and 
metabolic activity of transfected cells 
Transfection efficiency as well as polyplex toxicity of the polymers with increased 
m.w. was evaluated in vitro on B16F10 and Neuro2A cells. The relation between 
polymer size and efficiency of gene transfer became clearly visible when MK-A1/1 
was compared to its three fractions with different molecular masses. MK-A1/1-Fr.I, 
which is composed of the highest m.w. portion of MK-A1/1, showed transfection 
results clearly superior not only to the lower m.w. fractions but also to the non-
fractionated polymer on both cell lines (Figure 19A, C). While transfection efficiency 
rose from Fr.II and native MK-A1/1 to Fr.I, toxicity did not increase in parallel, and 
Fr.I showed the same high biocompatibility as MK-A1/1 or Fr.II. The same effect of 
enhanced transfection efficiency without increased toxicity was observed for MK-A 
polymers that were directly synthesized with increased m.w. (MK-A1.2/1 and MK-
A1.5/1). In cell culture experiments MK-A1.2/1 and MK-A1.5/1 showed results similar 
to MK-A1/1-Fr.I, exceeding native MK-A1/1 but not MK-A1/1-Fr.I (data not shown). 
Taken together, shifting the size of MK-A towards the higher m.w. range improved 
the polymer´s properties as gene vector. 
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Figure 19. In vitro transfection experiments with fractionated MK-A1/1: 
influence of molecular weight on in transfection efficiency (luciferase assay, A and C) 
and metabolic activity (MTT assay, B and D) in Neuro2A (upper figures) and B16F10 
cells (lower figures).  
Each bar represents the mean ± sd of three individual experiments, each performed 
in triplicate. Significances were calculated for Fr.I values in comparison to MK-A1/1, 
Fr.II, Fr.III and OEI800. § not determined; # values >350 and <550 RLU/10 000 cells; 
Ο 1250 RLU/10 000 cells. Statistics given in figure 19C refer to the comparison of Fr.I 
with Fr.II, Fr.III, MK-A1/1 and OEI800.  
 
3.3.1.2 Increased amine density: BM-B1/1, MK-B1/1 
a) Syntheses, chemical and biophysical analysis 
Apart from the size of the polymer itself, also the size of its monomer units can be 
changed. Utilization of larger monomers, for instance, leads to an enhancement of 
the amine density in the resulting polymer. 
BM-B1/1 and MK-B1/1 were therefore synthesized following the protocol for BM-A1/1 
or MK-A1/1 respectively, replacing OEI800 starting material by the larger PEI1.8K. 
Within the purification, the 3.5 kDa dialysis membrane was replaced by a 6-8 kDa cut 
off membrane. Freeze drying of the dialyzed products finally resulted in red-colored 
solids with yields of 68 % and 43 % in case of BM-B1/1 and MK-B1/1, respectively. 
According to SEC analysis on Superdex 75 and 200 columns, sizes of BM-B1/1 and 
MK-B1/1 polymers resembled to each other. Compared to the polymer sizes 
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determined for MK-A1/1 and BM-A1/1 they were shifted towards the higher m.w. 
range: the fraction of oligomeric sized components decreased in favour of the high 
m.w. fraction of ≥ 40 kDa. A peak maximum appeared around 10 kDa, another one 
at ≥ 50 kDa. To ensure validity of the data obtained by SEC on Superdex material, 
the acid-stable BM-B1/1 polymer was additionally analyzed on a Novema 300 
column. As already mentioned, this system requires an acidic mobile phase (pH 2.8) 
and is therefore not suitable for the analysis of acid-labile MK-B1/1. The analysis of 
BM-B1/1 resulted in Mn = 11.1 kDa and Mw = 108 kDa with a polydispersity of 9.8. 
For comparison: for BM-A1/1 we found Mn = 8.5 kDa and Mw = 36 kDa with a 
polydispersity of 4.2. These results confirmed the findings obtained by size exclusion 
on Superdex 75 and 200.  
To investigate DNA binding affinity of the PEI1.8K based polymers an EtBr exclusion 
assay was performed. Already PEI1.8K starting material itself bound to DNA 
stronger than the smaller OEI800. DNA compacting properties of the derived 
polymerization products MK-B1/1 and BM-B1/1 were equivalent to those of PEI1.8K 
in the EtBr exclusion assay (Figure 20) and only marginally stronger than those of 
the A-line polymers.  
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Figure 20. Ethidium bromide exclusion assay in HBG, pH 7.4. DNA binding 
affinity of the B-line: BM-B1/1, MK-B1/1 and PEI1.8K. Each point represents the 
mean ± sd of three experiments. 
 
 
b) In vitro transfection results (luciferase reporter gene expression) and 
metabolic activity of transfected cells 
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Transfection experiments with BM-B1/1 and MK-B1/1 in B16F10 cells showed 
improved in vitro transfection efficiency for the polymers with enhanced amine 
density compared to the corresponding OEI800 based counterparts (Figure 21). 
Again, an additional fractionation of MK-B1/1 influenced the transfection results 
favorably, but not to the same extend as it was the case for MK-A1/1. At a c/p ratio of 
2.5 – the optimal ratio for MK-B1/1 and MK-B1/1-Fr.I – these both polymers reached 
transfection levels in the range of the golden standard PEI22K at its optimal N/P ratio 
of 6. However, the improved transfection efficiency of MK-B polymers over MK-A 
was paid to some extend at the costs of an increased toxicity; thus, cell viability after 
treatment with MK-B1/1 (c/p ratio of 2.5) corresponded to that after treatment with 
PEI22K (N/P 6) (75 % and 73 % relative metabolic activity, respectively), or was only 
slightly higher (82 %) in case of MK-B1/1-Fr.I. 
Stable control polymer BM-B1/1 showed about the same transfection efficiency as its 
acid-labile analog MK-B1/1, but became more toxic at higher c/p ratios (≥ 5). 
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Figure 21. Evaluation of the in vitro transfection efficiency (luciferase assay, A) 
and toxicity (MTT assay, B) of MK-B1/1 (non-fractionated and fractionated) and 
BM-B1/1 polyplexes compared to MK-A1/1 in B16F10 cells. Each bar represents 
the mean ± sd of three individual experiments, each performed in triplicate. # 1.7 × 
103 RLU/103 cells. Statistics were calculated for the differences in transfection 
efficiency of MK-B1/1 and MK-A1/1. 
 
 
 
3.3.2 PEGylated polymers: PEG-BM-A1/1 and PEG-MK-A1/1 
a) Syntheses and biophysical analysis 
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Scheme 5. Syntheses of MK-A1/1, BM-A1/1 and their PEGylated variants PEG-
MK-A1/1 and PEG-BM-A1/1. In case of the PEGylated polymers, the linker is 
reacted first in 19-fold molar excess with PEG-SH before OEI is added. 
 
 
To introduce PEG into MK-A1/1 or BM-A1/1 (Scheme 5) 5 % (n/n) of the OEI800 
were replaced by thiol modified PEG of 5 kDa (PEG-SH). The purified and dried 
polymers appeared as pink cotton-like voluminous solids. PEG content as well as 
linker to OEI ratios in the resulting polymers were determined by 1H NMR analysis: 
for PEG-BM-A1/1 a proportion of 0.05/1.3/1 PEG/linker/OEI800 was found, while this 
ratio was 0.08/1.09/1 in case of PEG-MK-A1/1. An EtBr exclusion assay was 
performed in order to investigate if PEGylation hampers DNA binding capacity of the 
polymers. In this assay the presence of PEG caused no (c/p ratios ≥ 0.5) or only 
marginal (c/p < 0.5) impairment of DNA binding (Figure 22). 
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Figure 22. Ethidium bromide exclusion assay (HBG, pH 7.4). Influence of 
PEGylation on DNA binding: PEG does not or only slightly (at very low c/p ratios) 
hamper binding ability of the polymers. Each point represents the mean ± sd of three 
experiments. 
 
 
Next, the effect of PEG shielding on polyplex size and surface charge was 
investigated. Therefor, MK-A1/1 and BM-A1/1 conjugates with or without PEG were 
mixed in HBG with pDNA at several c/p ratios. Differences in particle size as well as 
in zeta potential were found for the PEGylated particles compared to the PEG-free 
ones. Upgraded particle stabilization upon PEGylation was noticeable especially in 
the low c/p range, where particles are compacted only loosely: while non-PEGylated 
polyplexes interacted with each other, showing rather big sizes at lower c/p ratios, 
PEGylated particles possessed constant small sizes around 100 nm independent 
from the c/p ratio (Figure 23A). The shielding effect of PEG became even more 
apparent when particles were analyzed for their surface charge. Here, PEGylated 
particles showed almost neutral zeta potentials over the whole c/p range tested, 
whereas surface charges of non-PEGylated polyplexes depended strongly on the c/p 
ratio and reached from negative values at c/p of 0.25 up to about +25 mV for c/p of 4 
or higher (Figure 23B). This study demonstrates that PEGylation of MK- and BM-
A1/1 polymers has been conducted successfully and the PEG content chosen is 
sufficient to achieve total shielding of MK-A1/1 and BM-A1/1 polyplexes. 
 - 73 - 
3 Results    
 
 
MK-A1/1
0
100
200
300
400
0 2 4 6 8
c/p
si
ze
[m
V]
A
-20
-10
0
10
20
30
40
0 2 4 6
c/p
ze
ta
[m
V
]
B
8
PEG-MK-A1/1
*
si
ze
[m
V]
ze
ta
[m
V
]
si
ze
[m
V]
ze
ta
[m
V
]
si
ze
[m
V]
si
ze
[m
V]
ze
ta
[m
V
]
ze
ta
[m
V
]
 
 
Figure 23. Determination of particle size (A) and surface charge (B) in presence 
or absence of PEG in HBG pH 7.4. Particles were either formed with MK-A1/1 
(black triangles) or PEG-MK-A1/1 (grey triangles) and pDNA at different c/p ratios. 
Nearly neutral zeta potentials and stable small particle sizes of the PEGylated 
particles demonstrate the shielding effect of PEG-MK-A1/1 compared to non-
PEGylated MK-A1/1. Each point represents the mean ± sd of three experiments. 
* aggregation (particles > 1 nm) at c/p ratios < 0.5. 
 
 
For the introduction of PEG into the polymers the same linkage (MK- or BM-linker 
respectively) was used as for the polymerization process of the polymer itself; 
therefore, in PEG-MK-A1/1 the PEG moiety is attached reversibly via the acetal 
linkage, while in PEG-BM-A1/1 the linkage is irreversible. As this effects polyplex 
shielding behaviour, shielding kinetics were examined in a further study. Polyplexes 
were prepared in HBG at c/p 1 and diluted either with buffer of pH 7.4 or with buffer 
of pH 5.0. The samples were then incubated at 37 °C for different time periods and 
changes in particle size and surface charge were analyzed. While PEG-MK-A1/1 
particles stayed stable at pH 7.4, in acidic medium these particles grew in size and 
finally aggregated; in parallel their zeta potential increased over time (Figure 24A). 
These data demonstrate that maleimido-acetal-linked PEG allows shielding in 
physiological fluids but at the same time is acid-reversible, which is of interest for 
endosomal deshielding of polyplexes. In contrast PEG-BM-A1/1 particles changed 
their characteristics neither at physiologic nor at acidic pH, which attests that 
PEGylation is stable in this case, independent from the existing pH (Figure 24B).  
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Figure 24. Particle size and surface charge of PEG-MK-A1/1 (A) and PEG-BM-
A1/1 (B) polyplexes (c/p = 1) measured at different time points after incubation 
at 37 °C. Measurements were performed either in 20 mM NaOAc pH 5.0 containing 
75 mM NaCl (left panels) or in 20 mM Hepes pH 7.4 containing 75 mM NaCl (right 
panels). Reversible PEGylation at pH 5.0 in case of PEG-MK-A1/1 (A, left panel). No 
removal of PEG from PEG-MK-A1/1 particles at physiologic pH (A, right panel).  
Polyplexes made of non-degradable PEG-BM-A1/1 stably shielded at both pHs (B). 
Each point or bar represents the mean ± sd of three experiments. 
 
 
b) In vitro transfection results (luciferase reporter gene expression, enhanced 
green fluorescent protein expression) and metabolic activity of transfected 
cells 
The effect of PEGylation of MK-A1/1 on polyplex efficiency in gene transfer was 
evaluated in B16F10 cells (Figure 25). Thereby PEG-MK-A1/1 was compared to 
non-PEGylated MK-A1/1 and to the stable analogs BM-A1/1 and PEG-BM-A1/1. In 
both cases – MK as well as BM polymer – PEGylation improved compatibility of the 
polyplexes in B16F10 cells significantly, especially at higher c/p ratios (Figure 25A). 
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PEG-MK-A1/1, basing on the degradable MK-A1/1 polymer, was thereby significantly 
less toxic than corresponding nondegradable PEG-BM-A1/1. Furthermore, the 
experiments demonstrated that not only PEGylation per se but also the kind of PEG 
linkage used (stable, labile), has an impact on transfection results. 
In terms of transfection efficiency (luciferase assay) PEGylation had a negative effect 
on the BM-linked polymer, thus reducing gene expression remarkably (Figure 25B). 
For MK-A1/1 in contrast, the reversible PEGylation improved transfection efficiency 
of the polymer; at high c/p ratios (12.5) PEG-MK-A1/1 even showed gene expression 
values comparable to those reached with PEI22K. At c/p ratios of 10 and 12.5 the 
superiority of PEG-MK-A1/1 was significant over all three other polymers (MK-A1/1, 
BM-A1/1 and PEG-MK-A1/1).  
 
re
l. 
m
et
ab
ol
ic
ac
tiv
ity
[%
]
A
PEI22K, N/P6
MK-A1/1
BM-A1/1
PEG-MK-A1/1
PEG-BM-A1/1
OEI800
# OEI800: 1E+3   
to 1E+4***
***
#
#
## #
B
1E+4
1E+5
1E+6
1E+7
1E+8
1.0 2.5 5.0 7.5 10.0 12.5
c/p
R
LU
/1
0 
00
0 
ce
lls
*** *** ***** ***
0
20
40
60
80
100
120 * ******
** *** * *** ***
re
l. 
m
et
ab
ol
ic
ac
tiv
ity
[%
]
R
LU
/1
0 
00
0 
ce
lls
R
LU
/1
0 
00
0 
ce
lls
R
LU
/1
0 
00
0 
ce
lls
R
LU
/1
0 
00
0 
ce
lls
 
 
Figure 25. Influence of PEGylation of MK-A1/1 and BM-A1/1 on transfection 
efficiency and polyplex toxicity in B16F10 cells. While stable PEGylation (PEG-
BM-A1/1) only improves polyplex compatibility but decreases transfection efficiency, 
acid-reversible PEGylation has positive effects on both features. The bars in the 
diagrams show the mean ± sd out of three individually performed experiments, each 
of them performed in triplicate. 
 
To further elucidate the differences between the four polymers, FACS analysis of 
pEGFP transfected B16F10 cells was performed (Figure 26). PEI22K polyplexes 
were used again at their optimal N/P ratio of 6, while for the OEI-based polymers a 
c/p ratio of 10 was chosen. The number of transfected cells was highest for the non-
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modified BM-A1/1 polymer (~ 60 %), followed by PEG-BM-A1/1, PEG-MK-A1/1, MK-
A1/1 and finally PEI22K, which varied only slightly in their numbers of transfected 
cells (30-20 %). One has to keep in mind that only viable cells are measured in this 
assay, while dead cells are not taken into account. Therefor, in contrast to the 
luciferase assay, the higher toxicity of BM polymers is not represented, which makes 
toxic polymers appear in a much better light. It is hence not reasonable to compare 
the results of toxic BM-linked polymers directly with those obtained for highly 
compatible MK-linked ones. Nevertheless, the study allows to gain some insight into 
the effects of PEGylation on the transfection properties of MK-A1/1 or BM-A1/1. 
Regarding the mean fluorescence intensity (MFI) per cell, stable PEGylation of BM-
A1/1 resulted in a loss of reporter gene expression also in this experiment: while for 
BM-A1/1 a MFI of 666 was measured, for PEG-BM-A1/1 this value was only about 
1/3 as high (MFI 252). Also the number of viable cells expressing EGFP decreased 
for about 50 % upon the introduction of a stable PEG shield. In contrast, acid-
reversible PEGylation of MK-A1/1 heightened the MFI-value from 466 (MK-A1/1) to 
600 (PEG-MK-A1/1) and no decrease in the number of transfected cells could be 
observed. Taken together, this study confirmed that transfection properties are 
affected positively by acid-labile PEGylation, while they worsen in the presence of 
stable PEG. 
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Figure 26. Enhanced green fluorescent protein (EGFP) gene expression in 
B16F10 cells. Polyplexes were prepared at c/p ratio of 10 (for PEI22K at N/P = 6) in 
HBG. The diagram shows a representative experiment, each point or bar 
demonstrates the mean of a triplicate. (MFI: mean fluorescence intensity). 
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3.3.3 Hexyl acrylate modification of MK-A1/1 and PEG-MK-A1/1 
a) Syntheses and biophysical analysis  
Six different polymers equipped with hydrophobic hexyl acrylate (HA) domains were 
synthesized: HA2.5-MK-A1/1, HA5-MK-A1/1, HA10-MK-A1/1 and HA2.5-PEG-MK-
A1/1, HA5-PEG-MK-A1/1, HA10-PEG-MK-A1/1. The nomenclatur of the polymers 
refers to the HA/OEI input ratios used (i.e. HA2.5 indicates an HA/OEI800 ratio of 
2.5/1) and to the polymer prototype the polymers are derived from (MK-A1/1 or PEG-
MK-A1/1). 
The initial step in the production of HA-polymers was the synthesis of MK-A1/1 or 
PEG-MK-A1/1. Instead of working up, the respective amounts of hexyl acrylate 
(HA/OEI input ratios: 2.5/1 for HA2.5 polymers, 5/1 for HA5 polymers and 10/1 for 
HA10 polymers) were added directly to the reaction mixtures of MK-A1/1 or PEG-
MK-A1/1 and the reaction was continued for another 3 h at elevated temperature 
(Scheme 6). The subsequent steps (dialysis, freeze drying) were performed as 
described for MK-A1/1. Depending on the amount of HA the resulting products 
differed in their physical properties: HA10 variants possessed viscous consistency, 
were transparent and of red to auburn colour; HA5 variants were also dark red or 
auburn but of much higher viscosity, nearly solid; HA2.5 polymers finally were pink 
and exhibited a voluminous cotton-like structure. In general, the PEGylated polymers 
showed darker colours than their non-PEGylated variants. While HA2.5 and HA5 
polymers could be dissolved in water quite easily, HA 10 polymers were soluble only 
at low concentrations of about 2 mg/mL and less.  
EtBr exclusion assay performed with all HA polymers indicated that HA does not 
interfere with the DNA binding of the polymers up to HA/OEI ratios of 5. For HA10-
MK-A1/1 in contrast – and even more for HA10-PEG-MK-A1/1 – DNA condensing 
ability was reduced remarkably. Measurements on particle size also suggested that 
polyplexes were more stable and compact, the less HA they contained; this is in 
accordance with the results from EtBr exclusion assay. Further, it was found that HA 
mediated no shielding effect and only additionally PEGylated particles exhibit neutral 
surface charges. 
 - 78 - 
3 Results    
 
 
N
O
O
O O
N
O
O
N
R
N
R
N
O
O
O O
N
O
O
N
R
N
n
 
R
S
N
O
O
O O
N
O
O
N
R
N
N
O
O
N
R
N
N
NH
N
N
O
O
R
O
O
O
O
n
 
O
O
OEI800
OEI800
OEI800
PEG
40°C, 3h
 
 
Scheme 6. Schematic illustration of the HA-modification of MK-A1/1 or PEG-
MK-A1/1. Hydrophobic hexyl acrylate residues are reacted onto MK-A1/1 or PEG-
MK-A1/1 polymers. R = H or oligoethylenimine units; hydrophobic HA moieties in the 
polymer are encircled in grey. 
 
 
b) In vitro transfection results (luciferase reporter gene expression) and 
metabolic activity of transfected cells 
The hydrophobic HA-MK and the amphiphilic HA-PEG-MK polymers were tested for 
gene transfer efficacy and toxicity on B16F10 and Neuro2A cells. Generally, all HA 
containing polymers showed increased toxicity compared to HA-free ones, with a 
direct correlation between HA amount and toxicity (Figure 27B). Interestingly, on 
B16F10 cells the PEGylated variants were even less compatible than the non-
PEGylated HA polymers. 
For some of the polymers transfection efficiency was enhanced compared to 
unmodified MK-A1/1. B16F10 cells for example showed highest gene expression up 
to 1 log unit below PEI22K with the both HA2.5 polymer variants. In contrast, in 
Neuro2A cells the highest transgene expression was obtained with HA10 variants 
and exceeded even the PEI22K standard (Figure 27A). HA5 modifications, however, 
were inefficient in both cell lines. Taking into account that – in case of high 
transfection efficiencies of HA polymers – the good biocompatibility of the original 
MK-A1/1 or PEG-MK-A1/1 polymers is completely deleted by the introduction of 
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hydrophobic HA moieties, the overall transfection efficiency/toxicity relation of HA-
MK-A1/1 and HA-PEG-MK-A1/1 shows no advantage over the original polymers. 
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Figure 27. Influence of hydrophobization of MK-A1/1 and PEG-MK-A1/1 
polymers on transfection efficiency and toxicity in Neuro2A cells. While HA-
modification in part could boost transgene expression, it also caused severe toxicity 
when used at high concentrations. 
Each bar represents the mean ± sd of three individual experiments each performed 
in triplicate. 
 
3.3.4 In vivo biocompatibility studies of PEGylated polymers 
The strategy of acid-sensitive PEGylation seemed to be the most promising concept 
concerning both, improved transfection efficiency and reduced polymer toxicity. 
Therefore, PEGylated MK and BM polymers were selected for further investigations 
on in vivo biocompatibility in mice. HBG-solutions of PEG-MK-A1/1 and its 
comparative polymers BM-A1/1, PEG-BM-A1/1 and MK-A1/1 were administered to 
8-weeks old female Balb/c mice via tail vain injection. As mentioned previously, 
treatment with 100 µg polymer/20 g mouse is lethal in case of BM-A1/1. Dose 
reduction to 50 µg still induced the development of a fatty liver (Figure 28A, upper 
left picture A). PEGylation of the polymer (PEG-BM-A1/1) resulted in an improved 
biocompatibility: the dosage of 50 µg/20 g mouse was well tolerated by all three 
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animals and no pathological changes were observed in liver tissue (Figure 28A, 
upper right picture B).  However, treatment with 100 µg of PEG-BM-A1/1 was 
survived only by one mouse out of three. This indicates that despite PEGylation 
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 Figure 28. In vivo study on toxicity of the free polymers in Balb/c mice. (A) 
Histological examination on liver tissue (hematoxylin-eosin staining) 48 h after i.v. 
administration of indicated amounts of free polymer per 20 g mouse. Development of 
a fatty liver (black arrows indicate lipid droplets in hepatocytes) after application of 50 
µg of non-degradable unPEGylated BM-A1/1 polymer (upper left picture). Its 
PEGylated variant (PEG-BM-A1/1, upper right picture) in contrast was well tolerated, 
no inclusion of lipid droplets in liver tissue can be observed. Degradable MK-A1/1 
and PEG-MK-A1/1 polymers (lower left and right pictures, respectively) induced no 
or only marginal histopathological changes in the liver, even at dosages of 100 µg. 
(B) AST level in serum of mice treated with the indicated polymers at a dosage of 50 
µg/20 g mouse. Number of mice for each treatment group: n = 3. 
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considerable toxicity remains due to the non-degradability of the polymer. 
Degradable MK-A1/1, in contrast, is known as highly compatible polymer, tolerated 
even at the 100 µg dosage by all three mice treated (Figure 28A, lower left picture 
C); only in one of them the onset of a fatty liver was detectable. For the PEGylated 
variant PEG-MK-A1/1 (Figure 28A, lower right picture D) the results were very 
similar; again one mouse out of three developed a fatty liver and two retained 
completely healthy liver tissue. The other harvested organs (lung, kidneys) were not 
affected by the treatment with any of the polymers and did not show any 
histopathological changes. 
Additionally, the levels of the liver enzymes alkaline phosphatase (AP) and aspartate 
aminotransaminase (AST) were determined in the plasma of the mice. Elevated 
values of these enzymes indicate liver damage. In case of AP no significant 
differences could be detected in animals treated with MK-A1/1, PEG-MK-A1/1, BM-
A1/1 or PEG-BM-A1/1 (dosage: 50 µg/20 g mouse). In contrast, the AST level 
(Figure 28B) of BM-A1/1-treated mice was significantly (p < 0.01) enhanced over 
that of non-treated control mice, demonstrating destruction of liver tissue by this 
polymer. PEGylation of BM-A1/1, however, could reduce the AST level significantly 
(p < 0.05). AST levels of mice treated with PEG-BM-A1/1, MK-A1/1 or PEG-MK-A1/1 
did not differ significantly from those of untreated control mice. This confirms again 
the advantage of polymer degradability and PEGylation with regard to an improved 
biocompatibility.
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4 Discussion 
Recent strategies to improve drug and gene delivery systems focus on the design of 
more dynamic “stimuli-responsive” formulations (1, 3). Similar as viruses in their 
infection process, these formulations may undergo programmed structural changes 
(45, 56, 91), which are induced by the particular micro-environment such as an 
intracellular reductive environment (92-94), enzymes (95), altered pH (53, 56, 96), or 
are introduced externally by physical means (eg. temperature, light or magnetic 
field). The acidification of endosomes has been capitalized to trigger hydrolysis of 
acid-labile bonds in drug carriers and conjugates, such as ortho esters (53, 97, 98), 
acetals (55-57) or hydrazones (50, 96, 99). Their high adaptiveness make this kind 
of systems so successful. 
 
4.1 Development of a versatile pH-sensitive PEGylation reagent 
and its application on polyplexes  
 
Among other applications, the strategy of the stimuli responsive system has been 
used for pH-determined intracellular deshielding of non-viral gene vectors (100). 
Surface shielding of gene vectors by PEG (81) or other hydrophilic polymers (101) 
has been found to be very helpful for systemic circulation and reduced toxicity, but 
hampers intracellular delivery. Therefore removal of the shield after delivery of the 
gene vector to the target cell would be desirable.  
 
4.1.1 Synthesis and characterization of PEG-A-MAL as a novel acid-sensitive 
PEGylation reagent 
In this work the synthesis of a new acetal linked PEGylation reagent is described, 
that undergoes acidic triggered cleavage and is shown to be advantageous for 
reversible shielding of gene delivery particles. The novel PEGylation reagent 9 was 
synthesized following the steps shown in Scheme 1, after synthetic procedures were 
established using 2-methoxyethanol instead of mPEG. The Buchwald Hartwig cross 
coupling reaction is a powerful method for substitution of aromatic bromines with 
piperazine (102). In this report the Buchwald Hartwig amination reaction for 
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substitution of the p-bromobenzaldehyde mPEG acetal with the monoprotected 
piperazine proved to be an efficient procedure affording the desired product with an 
82 % yield. To our knowledge it is the first Buchwald Hartwig cross coupling reaction 
with a polymeric compound. 
The pH existing in endosomes varies with the type of endosomal vesicle and the 
applied formulation (84, 84, 85). Therefore hydrolysis studies with PEG-A-MAL were 
performed at several pHs to determine changes in the hydrolysis rate in dependence 
of the pH. As shown in Figure 4A PEG-A-MAL hydrolysis underlied a strong pH 
specificity with a half-life of approximately 1 h at pH 7.4 and  less than 3 min at pH 5. 
At pH 5.5 and 6, approximately the pHs existing in PEI containing endosomes (84, 
85), PEG-A-MAL degraded with a half-life of less than 5 and 10 min, respectively 
(Figure 4A). Figure 4B shows the hydrolysis rates of PEG-A-MAL at defined time 
points as a function of the pH. For pH 5 at all three time points – 5, 10 and 15 min – 
the reagent showed almost complete degradation, while for pH 7.0 between 96 and 
80 % remained intact during the indicated time periods. These data clearly 
demonstrate the pH dependence of the degradation rate of PEG-A-MAL. 
 
4.1.2 Acid-labile PEGylation of polyplexes 
Since these hydrolytic studies showed the PEG-A-MAL linker to be suitable for acid-
specific hydrolysis, the reagent was used for PEGylation of different mercapto-
modified polycations, used as transfection reagents. Thereby, the reagent turned out 
to be compatible with all polycations tested, including PEIs. This highlights the 
versatility of the reagent, and points out the benefit over similar reagents which could 
not be coupled to PEI (50). Kinetic hydrolysis studies performed with the PEG-A-
PEI25K conjugate showed similar pH specificity (at 37 °C, half-life of about 2 h at pH 
7.4, and 3 min at pH 5.5) as found for PEG-A-MAL. Thus this conjugate provides 
sufficient storage stability on the one hand and allows polyplex deshielding even in 
PEI-buffered endosomes of pH 5.5 to 6 on the other hand. This observation was 
made both for branched PEI25k (this work) and linear PEI22K conjugates (data not 
shown) and contrasts to previous work with acid-labile hydrazone linkers, where PEI 
triggered pronounced hydrolysis of the linker also at neutral pH (50).  
From previous work (50, 81) it is known that for the shielding of polyplexes it is often 
not necessary to substitute all the polycation by its PEGylated version. As the 
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amount of the PEG conjugate needed depends on the amount of PEG on the 
polycation as well as the PEG chain length and sort of polycation, we investigated 
empirically which would be the optimal ratio for the different PEG-A-polycation 
conjugates. In titration experiments with varying amounts of PEG-A-polycation in the 
polyplexes the optimal amount of shielding conjugate in the formulation was 
determined. Ideal ratios ranged between 20 and 30 %, depending on the conjugate 
used. For polyplexes composed of unmodified PEI22K and PEG-A-PEI25K for 
example, 20 % of the PEG-conjugate containing 1.5 acetals, i.e. 3 PEG chains per 
PEI, were found to be most convenient. With this amount of PEG polyplexes showed 
proper and persistent shielding at physiological pH but at the same time were 
deshielded quickly at the acidic pH of 5. The acid-labile PEG-A-PEI25K conjugate, 
which was chosen for further experiments, was then incorporated into DNA 
polyplexes additionally containing the targeting conjugates EGF-PEI or Tf-PEI to 
investigate if the acid-labile PEG is also compatible with EGF- and Tf-ligands. As the 
polyplexes retained their pH-specific deshielding characteristics also in presence of 
the targeting conjugates, they were finally tested for receptor mediated uptake into 
cells. EGF containing polyplexes and Tf containing polyplexes have been previously 
shown to be efficiently internalized into EGFR-overexpressing Renca cells (83, 103) 
and transferrin receptor overexpressing K562 cells (74, 81), respectively. To obtain 
sufficient surface neutralization the pH-sensitive (PEG-A-PEI25K) or non-reversible 
(PEG-S-PEI25K) shielding conjugate was included into the polyplex at 20 % (w/w; 
PEI); resulting in well-shielded particles with a zeta potential of +3 mV and particle 
sizes in the range of 200 nm. In order to follow the deshielding process, these 
particles were incubated at pH 7.4, representing the physiological pH of the blood, or 
at pH 5, representing endosomal pH. At pH 7.4 all polyplexes maintained their PEG 
shield for the 2 h time period, a time spread after which receptor mediated uptake 
should be completed (104). At pH 7.4 additional analysis of the polyplexes after 4 h 
was performed (data not shown) to assure stability of the PEG shield during the 
incubation time in cell culture experiments. Polyplexes did not deshield within this 
time. Also the polyplexes containing the non-reversible shielding conjugate PEG-S-
PEI25K did not change their biophysical properties at pH 5 (data not shown). In 
contrast, the particles containing PEG-A-PEI25K at pH 5 within 30 min formed 
aggregates and increased in zeta potential, indicating deshielding. The reversibly 
shielded (PEG-A-PEI25K) polyplexes were found to have approximately 10-fold 
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enhanced gene transfer efficiency compared to stably shielded polyplexes when 
tested on the two different cell lines, Renca-EGFR cells and K562 cells. This 
enhancement is not due to extracellular polyplex deshielding, as transfection 
medium was replaced by fresh culture medium within a time period where PEG 
shield is still intact, but due to intracellular PEG removal. Further evidence therefore 
gave transfection results of experiments where medium was changes already after 
two hours. Here the same trends in transfection efficiency were obtained (data not 
shown). This is consistent also with previous results using pH-labile hydrazone 
linkages (50). The novel PEG-A-MAL reagent 9 described in this study, however, 
presents a more versatile tool for pH-sensitive PEGylation.  
 
4.1.3 Outlook 
Beyond the polycations investigated in this study other mercapto-modified 
compounds may be modified for the development of more dynamic, pH-responsive 
drug and gene delivery systems. PEGylation is, in any case, a technique becoming 
more and more popular not only regarding gene therapy, but also in other areas of 
medicine. Especially in case of the emerging group of biotech protein drugs as for 
example cytokines (interferons, interleukins, grows factors, erythropoietin), 
hormones (insulin) or antibodies (105) (Table 3), PEGylation is a preferential 
technique. It affords enhanced stability (physically, chemically, proteolytically) and 
solubility, improved bioavailability (concerning absorption, renal filtration, 
immunological clearance) and reduced toxicity (immunogenicity, antigenicity).  
 
symptomatic anemia in adult patients
with chronic kidney disease
PEG + erythropoietin betaRocheMircera ®
rheumatoid arthritis and Crohn's
disease
PEG + antiTNF-α humanized antibody fragmentUCB PharmaCimzia ®
acute lymphatic leukemiaPEG +    -asparaginasemedacOncaspar ®
severe combined immunodeficiency
disease
PEG 5 kDa + adenosine deaminaseEnzonAdagen ®
acromegalyPEG + human growth hormone receptor antagonistPfizerSomavert ®
hepatitis-CPEG 12 kDa + interferon α-2bSchering PloughPegIntron ®
hepatitis-CPEG 40 kDa + interferon α-2aRochePegasys ®
chemotherapy associated neutropeniaPEG 20 kDa + granulocyte colonystimulating factorAmgenNeulasta ®
indicationdrugcompanyname
L
 
Table 3.  Examples for PEGylated protein drugs on the market (106). 
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However, proteins as for example enzymes are biologically active substances, 
whose activity depends on the accessibility of an active site in the molecule. 
Consequently, covalent attachment of large molecules like PEG might hamper 
biological activity. In this case, reversible PEGylation with versatile reagents like 
PEG-A-MAL might be of interest. These reagents are applicable not only for 
endosomal targeting, but also other sites of decreased pH can be addressed like 
tumors (107), infarct sites (108) or inflamed tissue (109). Acid reversible PEGylation 
thus demonstrates an exiting tool for various fields of application. 
  
4.2 Degradable gene vectors for improved biocompatibility  
Polycations used as non-viral vectors often suffer from low gene transfer efficiency 
or – if they are efficient – possess considerable toxicity. Thus, it is a major challenge 
in non-viral gene therapy to combine both desired qualities in one vector – the 
required efficiency of high molecular weight polycations like PEI22K, and the good 
biocompatibility of low molecular weight oligocations (33). The aim of this work was 
to design degradable polycations of appreciable size, which are composed of small 
oligomeric units connected via reversible acetal linkages. While maintaining their 
high molecular weight in the extracellular space, thus providing efficient protection 
and tight packaging of the nucleic acid and mediating its uptake into the cell, 
intracellularly these vectors should degrade into small biocompatible decomposition 
products. Different approaches (i.e. vectors decomposing with different velocities 
and upon different stimuli) have already been investigated, but currently the optimal 
specific timing (minutes, hours or days) and location of such a degradation (vesicles, 
cytoplasm, nucleus) remain unclear (54, 84). For example, vector decomposition 
depending on endosomal milieu, has to proceed fast enough to ensure that polymer 
degradation is complete before endosomal release into the pH-neutral cytoplasm 
takes place. This means, vector decomposition has to occur within a quite short time 
scale (minutes to less than an hour), as an efficient endosomal release of polyplexes 
must take place before the endosome matures into an endolysosome destroying the 
delivered nucleic acid. Too rapid degradation of the polymeric carrier which protects 
the nucleic acid and facilitates its release from the endosome would also be 
counterproductive. In essence, concerted polymer degradation and endosomal 
release is hypothesized to be preferred for pH-sensitive carriers. Moreover, it is 
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difficult to make general statements on optimal location and timing, as the demands 
depend on the particular objective and target (endosomal DNA delivery / cytoplasmic 
RNA delivery) and also on the cell type. It also remains to be determined in which 
specific case which molecular trigger for degradation (reductive cleavage of disulfide 
bonds (54, 92), cleavage upon acidification (67-69, 110), hydrolysis of ester bonds 
(33, 60, 63, 111)) is most suitable, alone or in combination. 
Disulfide containing vectors for example, which respond with degradation to 
reductive environment, are widely used. These systems claim to be stable when 
circulating in the oxidizing extracellular space but disintegrate when taken up into 
reducing intracellular compartments as the cytosol, the nucleus and in endo-
/lysosomes. However, cleavage of the disulfide bond also can occur already before 
the vehicle is taken up into the cell. It is known that disulfide reduction of 
macromolecules yet begins at the cell surface, due to cell surface-associated redox 
enzymes expressed at the plasma membrane (54, 92). Reduction at the outside of 
the cell would cause a loss of DNA due to inadequate cellular uptake and lead to 
degradation of the insufficiently protected DNA. Saito et al. (92) also reported from a 
group that observed rapid cleavage of disulfides already in the blood (112). The 
disulfide bond can be made more stable by introducing sterically challenging 
shielding moieties in order to prevent the preterm reduction. However, this is a 
delicate operation, as the disulfide bonds might than easily become too stable for the 
intracellular cleavage resulting in an inefficient decondensation of DNA complexes in 
the endosome and a decreased endosomal escape (92). These facts might be 
especially problematic as the intracellular level of the reducing agent glutathione 
strongly depends on the tissue type and therefore varies considerably between 
different cell lines (113).  
Another kind of biodegradable polymer is based on esters as cleavable linker 
moieties. These vector systems undergo unspecific hydrolysis in aqueous 
environment or are degraded by esterases. Degradation of esters takes longer than 
that of disulfides, as esters possess half-lives in the range of days (60); therefore 
these vectors have positive influence rather on the long term toxicity than on the 
acute one. Additionally, degradation of ester based polymers is also not fast enough 
to facilitate the release of DNA from the complexes inside the cell which might 
hamper the nuclear import. Finally, ester hydrolysis can occur extracellularly as well 
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as intracellularly and therefore shows no specificity to any special targeted 
compartment.  
A class of gene vectors designed to degrade rapidly upon a specific stimulus in the 
endosome but to remain stable during the circulation in the blood, are the pH-
sensitive vectors. However, these vectors are still rather rare. A main reason 
therefore surely is the lack of suitable linkages, that show appropriate rapid hydrolsis 
induced by only a slight decrease in pH as it is existent between cytosol and 
endosomes (1). In the current work we focused on this acidification of endosomal 
compartments as a specific trigger for polymer degradation.  
 
4.2.1 Design, synthesis and characterization of acid-degradable acetal based 
polycations for use as gene vectors 
For this purpose two different acetal based linkers (BAA and MK) were chosen, by 
which OEI800 units were oligomerized in order to obtain larger acid-hydrolyzable 
polymers. The acetone ketal containing linker MK (70) has previously been 
introduced as reversible protein cross-linking agent, the p-methoxy-benzaldehyde 
acetal diacrylate ester BAA (71) has been applied before in acid-cleavable polymer 
particles. In case of BAA, the obtained OEI-BAA polymers contain both the acid-
labile acetal groups and hydrolyzable ester groups. If polyplexes might not be 
degraded completely until they are released from the endosome, the remaining 
polymer can be hydrolyzed in the cytosol by ester hydrolysis also at neutral pH. 
Studies on the acetal cleavage confirmed that the acetal containing polymers MK-
OEI and BAA-OEI degrade in a pH-dependent manner, with very fast degradation 
kinetics in the acidic environment of pH 5 (approximately 3 minute half-life at body 
temperature) and much slower at physiological pH of 7.4 (3.5 hours half-life for OEI-
BAA and 5 hours for OEI-MK). In contrast, the acid-stable control polymers OEI-BM 
(for OEI-MK) and LT-OEI-HD (for OEI-BAA) degraded under the same acidic 
conditions either very slowly (LT-OEI-HD) or not at all (OEI-BM).  
With regard to their application as gene vectors, DNA binding and compacting 
capacity of the polymers was determined by ethidium bromide (EtBr) exclusion 
assay and by particle size and zeta potential analysis. At c/p ratios >1 stable, 
positively charged particles (i.e. sizes of 100-300 nm, positive zeta potential of 23 – 
30 mV)) were obtained in salt-free buffer. The EtBr exclusion assay correlated well 
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with the size measurements: for polymers that showed weaker DNA-binding affinity 
(e.g. OEI-BAA polymers) in the EtBr assay, slightly larger particles were detected by 
size measurements than for those made from polymers with high DNA-binding ability 
(e.g. MK-A1/1). The firmer the DNA was condensed by the polycation, the smaller 
the polyplexes were in size. To further elucidate if there is a difference between 
polymers with high and low DNA-binding affinity, the influence of ionic strength on 
the polyplexes was investigated. Sizes of polyplexes from polymers with strong DNA 
binding (MK-A1/1, BM-A1/1) were not influenced by the addition of salt, while those 
prepared from weakly DNA-binding polymers (BAA polymers, at low c/p also LT-OEI-
HD) started to grow in size and aggregated, as it is also known for standard PEIs 
(114, 115). Overall, the polyplexes showed biophysical characteristics in the range of 
standard PEI22K particles and thus should be suitable for use as gene vectors. 
Polyplex transfection efficiency and toxicity were tested using B16F10 and Neuro2A 
cells. Concerning the compatibility of the formulations, the acid-degradable polymers 
showed a clear advantage over acid-stable analogs: the acetal containing polymers 
(OEI-MK and OEI-BAA) were significantly less toxic than their stable controls. This 
effect became more apparent with increasing c/p ratios. Regarding gene transfer 
efficiency, we found that polymerization of the very poorly transfecting OEI800 to 
larger polycations boosts transfection efficiency levels dramatically, both for acid-
stable linkages (OEI-BM, LT-OEI-HD) as well as for the acid-degradable (OEI-MK, 
OEI-BAA) ones. Due to better biocompatibility, for acid-labile polymers the c/p ratios 
leading to maximum transfection efficiency were slightly higher than for the stable 
counterparts. 
The OEI-BAA polymer series, containing both the acid-labile methoxy-benzaldehyde 
acetal and hydrolyzable ß-aminopropionic ester bond, displayed the most 
encouraging potential as transfection agent. For example, polymer BAA-2/1-3d 
mediated gene transfer more effectively than the control ester polymer LT-OEI-HD 
(with similar m.w.) at all c/p ratios tested. The smaller polymer BAA-1/1-3d which 
showed lower transfection efficiency at low c/p, with increasing c/p ratio exceeded 
not only BAA-2/1-3d, but also the golden standard linear PEI22K; however, the 
stability of BAA-1/1-3d polyplexes against aggregation needs to be improved. In 
contrast, the BAA-1/1-1.5d variant provides stable polyplexes. While these are less 
effective than BAA-2/1-3d polyplexes at low concentration, they reach comparable 
values at higher c/p ratios, without mediating any toxicity. This makes especially the 
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BAA-1/1-1.5d polymer interesting concerning the promising efficiency/toxicity 
balance. 
In Neuro2A cells, a general low transfection efficiency of medium-sized polyplexes 
(formed in HBG) is observed, presumably resulting from a general insufficient 
polyplex cellular uptake. This can be overcome by salt-induced aggregated 
polyplexes of PEI22K and OEI-BAA polymers. Once more, BAA polymers provided 
highest gene expression levels, at lowest cytotoxicity.  
Additionally, for BAA-2/1-3d as a representative for the BAA line, and for MK-A1/1 
the influence of the proton pump inhibitor bafilomycin A1 on transfection efficiency 
was investigated. Reporter gene expression of BAA-2/1-3d polyplexes in B16F10 
cells was diminished significantly by the inhibition of endosomal acidification. The 
same was also observable for PEI22K, where the lack of proton influx into the 
endosome prevents performance of the proton sponge effect of PEI (87). The fact 
that bafilomycin A1 has the same impact on transfection efficiency of PEI22K as of 
BAA-2/1-3d polyplexes suggests, that also for BAA polymers high transfection levels 
rely at least partially on their ability to capture protons. In contrast, bafilomycin 
caused no significant alterations on gene expression of MK-A1/1 polyplexes, 
implying that in this case proton sponge activity does not play a decisive role for 
transfection efficiency. 
In vivo toxicity studies with the free polymers confirmed the encouraging 
biocompatibility of the acetal containing polymers, found the in vitro experiments. 
Dosages (100 µg/20 g mouse) which were lethal in case of BM-A1/1, PEI25K or 
PEI22K and caused severe damage in liver tissue in case of LT-OEI-HD, were well 
tolerated in case of MK-A1/1 and BAA-2/1-3d polymers. This emphasizes the 
advantage of acid-degradable polymers over the controls also in vivo and makes 
them interesting candidates for use as safe gene transfer agents in vivo. 
Effectiveness in the in vivo situation however remains to be evaluated.  
Taken together, these data clearly show an advantage of degradable acetal-linked 
polymers compared to acid-stable ones. The chosen acetal linkage exhibits 
favorable hydrolysis kinetics: the synthesized polymers provide adequate stability for 
DNA polyplex formation resulting in efficient gene transfer in vitro, but also sensitivity 
towards a slight decrease in pH in endosomes, which causes polymer degradation 
and thus improves biocompatibility. Potential bottlenecks beyond biodegradability, 
like particle aggregation in salt, insufficient endosomal uptake of polyplexes or 
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deficient endosomal release are challenges that have to be managed by a 
sophisticated design of the polyplexes. Insufficient endocytosis of polyplexes might 
be overcome by the integration of suitable ligands to boost specific polyplex uptake 
into the target cells. Deficient endosomal release, which is still a major limit even for 
PEI-type polymers despite their proton sponge activity (85), might be overcome by 
incorporation of endosomally active components (116-118). Inadvertent particle 
aggregation can be prevented by pH-responsive PEGylation (50, 110, 117). Such 
strategies have to be investigated in the context of the polymeric carriers presented 
here, to yield polyplexes with suitable characteristics for in vivo gene transfer. 
 
4.2.2 Optimization of the physicochemical properties of MK-1/1 for improved 
transfection properties  
The MK-A1/1 polymer seemed to provide an excellent starting point for further 
optimization attempts. This polycation shows the high biocompatibility of degradable 
polymers outclassing common PEI polymers in this regard, but its efficiency is rather 
low compared to the golden standard PEI22K. To improve transfection properties, 
the following different aspects were considered to deserve closer attention and were 
therefore analyzed separately: 
4.2.2.1 Increased size and amine density 
A direct correlation between molecular weight and transfection efficiency has been 
reported previously by different groups (33, 59) and seemed to be interesting also for 
MK-A1/1. While MK-A1/1 by far exceeds OEI800 concerning polymer size, it is still 
inferior to standard PEI22 or PEI25, due to considerable polymer fractions in the low 
m.w. range. Consequently, decreasing the ratio of these low m.w. fractions in favour 
of the high m.w. fractions might improve the polymer`s characteristics. Indeed, 
independent of the method of increasing the average m.w. (fractionation of MK-A1/1 
or direct synthesis of polymers with larger sizes like MK-A1.2/1, MK-A1.5/1), this 
procedure led to remarkable improvements in transfection efficiency especially at low 
c/p ratios. For the application of higher amounts of cross-linker in the polymer 
syntheses (MK-A1.2/1, MK-A1.5/1) there is set an upper limit. Former research has 
already demonstrated that, depending on the linker and the monomer units chosen, 
there exists a particular limit for the linker/monomer ratio upon which gelation occurs 
(60). Actually, the fractionation method is especially interesting because not only the 
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polymer size but also its polydispersity is influenced favorably, thus making the 
polymer molecularly better defined (119). Despite the positive influence on 
transfection efficiency by the increased m.w., the high biocompatibility of the MK-A 
polymer is not affected negatively at all. 
Another aspect to mention in this context is the proton sponge activity, found for 
example for the highly efficient PEI polymers (49, 58). This attribute facilitates 
endsosomal release and is associated with a high density of protonable amines. The 
amine density of a polymer can be influenced by the size of the monomeric units it is 
composed of: when MK-A1/1 is synthesized, in the polymerization process primary 
amines of OEI800 react via Michael addition with the maleimido functions of the 
cross-linker. This results in a loss of protonable OEI800-amines in the polymer, 
which is unfavorable regarding DNA compacting ability (60, 120) and endosomal 
escape mechanisms (49). Additionally, the presence of quite spacious linker 
molecules further decreases the amine density in a polymer compared to an analog 
linker-free polymer. In case of MK-A1/1 this can be in part antagonized by replacing 
the OEI800 by larger PEI1.8K units. That way, the ratio of protonable amines/linker 
molecules is shifted towards the amines, i.e. to an increased density of amines. This 
facilitates the efficient compaction of DNA into small, stable polyplexes essential for 
the protection of DNA, efficient cellular uptake and – in conclusion – for efficient 
gene transfer. It has to be taken into account that the enhancement of amine density 
is a tightrope walk, as very high charge densities, found for example in PEI22K, 
PEI25K or PEI750K, destroy cellular membranes and therefore make polymers toxic 
(31). Indeed, also for BM-B1/1 and MK-B1/1 it is not only the transfection efficiency 
that rises, but also toxicity shows a slight increase, compared to the corresponding 
OEI800 based polymers (BM-A1/1 and MK-A1/1). It remains to be investigated 
whether this lower polymer compatibility can be overcome for example by 
PEGylating the polymers. This seems to be probable, as PEGylation was also 
applied successfully in case of BM-A1/1 and MK-A1/1. 
 
 
4.2.2.2 PEGylation 
PEGylation is a common method to reduce toxic effects of polyplexes (38), but has 
the drawback of abrogating transfection efficiency at the same time (39, 100). As 
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mentioned above, this handicap can be circumvented by reversibly linking the PEG 
onto the polycation. PEG, which prevents polyplex toxicity and provides particle 
stabilization during the circulation, finally is cleaved upon a defined stimulus and 
does not hamper subsequent steps of the transfection process. It has been 
demonstrated that transfection efficiency of PEI polyplexes could be restored by acid 
cleavable PEG-shieldings in the past (50, 110). Mostly, such a reversible PEGylation 
requires supplementary synthesis steps or special, sophisticated PEGylation 
reagents. In our case, the introduction of a pH-responsive PEG-shield into the MK-
A1/1 polymer was a simple procedure as it could be performed concomitantly to the 
synthesis of the polymer itself, thus avoiding additional purification and production 
steps. In contrast to the control polymer PEG-BM-A1/1, where the stable PEGylation 
lowered polymer toxicity and also transfection efficiency, the acid-labile PEGylation 
in MK-A1/1 surprisingly not only reduced toxicity, but also improved transfection 
efficiency compared to the non-PEGylated MK-A1/1. Further, PEG-MK-A1/1 was 
well tolerated also in vivo, when tested for biocompatibility in Balb-c mice. It 
represents therefore an interesting candidate for future transfection experiment in 
vivo. 
4.2.2.3 Hydrophobization 
According to viruses, which possess special membrane disruptive domains to 
facilitate their endosomal release, MK polymers were also equipped with such a 
feature. It is known from literature that hydrocarbon chains, applied in this context, 
can boost transfection efficiency of polycations (121, 122). Therefore different 
amounts of membrane active, hydrophobic hexyl acrylate moieties were reacted onto 
MK-A1/1 or PEG-MK-A1/1. While low amounts of HA (HA/OEI ratio of 2.5/1) had no 
appreciable influence on in vitro transfection efficiency or toxicity, high amounts (10/1 
ratio) caused extreme toxicity. Interestingly, it was observed, that PEGylated HA 
variants tended to exhibited slightly higher toxicity than PEG-free analogs. This might 
be explained by a pronounced tenside-like effect of polymers that combine 
hydrophilic (PEG) and hydrophobic (HA) moieties. With their highly surface-active 
characteristics these polymers might cause substantial damage in cell membranes, 
subsequently leading to cell death. Even though some of these polymers showed 
surprisingly high transfection levels, exceeding the golden standard PEI22K, they are 
– in this form – not convenient for use as gene vectors due to their high toxicity. 
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Here, further efforts are necessary to restore the high biocompatibility of the original 
MK-A1/1. 
 
Taken together, we applied different methods to improve transfection efficiency of 
the highly compatible acid-degradable gene vector MK-A1/1. Increasing m.w. or 
amine density of MK-A1/1, as well as the attachment of acid-cleavable PEG, turned 
out to be encouraging methods to boost reporter gene expression in vitro. Especially 
the pH-sensitive PEGylation turned out to be very promising and is worth to be 
examined in in vivo transfection experiments. 
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5 Summary 
Non-viral gene delivery systems have emerged to promising tools in gene therapy. 
Despite many advantages of non-viral vectors over viral ones, it still rests a major 
challenge to boost transfection efficiency to the levels obtained by virus mediated 
gene transfer. Hence it appears obvious to adopt the characteristics of non-viral 
vectors to those of viruses. This implies the incorporation of bioresponsive elements, 
which confer to the system a higher flexibility and permit to cope with the different – 
often even oppositional – requirements the vector has to meet before reaching its 
target. The aim of this thesis was accordingly to equip “artificial viruses” with pH-
sensitivity. By the application of acetal chemistry this concept was realized, 
regarding two different aspects: firstly the acid-reversible PEGylation of polyplexes, 
and secondly the acid-triggered degradation of polymeric gene carriers. 
PEGylation prevents polyplexes from undesired interactions, both with physiological 
components in the patient and among themselves. On the other hand stable PEG 
shielding hampers endosomal release of endocytosed complexes and diminishes 
transfection efficiency. In contrast, the PEG-A-MAL reagent developed in this work, 
allows to PEGylate polycations reversibly, providing stable polyplex shielding in the 
extracellular compartments but, after cleavage upon acidification in the endosome, 
facilitating endosomal release. The reagent was compatible with different kinds of 
polycations commonly used as gene vectors (e.g. PEI, PLL) and also tolerated the 
concomitance of targeting ligands. In cell culture experiments on two different cell 
lines transfection efficiency was enhanced 5- to 14-fold with PEG-A-MAL shielded 
polyplexes compared to stably shielded analogs, highlighting the potential of this 
versatile reagent. 
In terms of improved vector biocompatibility degradable systems have recently 
attracted more and more interest. Herein, vectors composed of oligoethylenimine 
units cross-linked via acetal containing linkers are described. The acid cleavable 
acetal functions provide appropriate hydrolysis kinetics for polymer degradation upon 
a slight drop of pH, as it occurs in endosomes. Two polymer lines have been 
established: the MK-line based on an acetone ketal and the BAA-line based on a p-
methoxy-benzaldehyde acetal. Both variants showed significantly reduced toxicity 
compared to stable analogues in cell culture experiments. Transfection efficiency of 
the novel polymers was promising, especially in case of some BAA polymers which 
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were able to compete with the golden standard PEI22K. In case of MK polymers, 
alterations in the physicochemical properties could further enhance transfection 
efficiency. The most promising approach represented the acid-sensitive PEGylation 
of MK-A1/1, which could be achieved conveniently in a one-step synthesis. The 
resulting polymer showed not only increased gene transfer efficiency but also 
reduced toxicity. 
Selected polymers were finally tested for biocompatibility in vivo. Liver tissue 
analysis of mice treated with the plain polymers confirmed the improved tolerance of 
acid degradable polymers over acid-stable analogs. 
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6.1 Abbreviations 
AP    alkaline phosphatase 
AST    aspartate aminotransaminase 
BAA 1,1-bis-(2-acryloyloxy ethoxy)-[4-methoxy-phenyl]meth-
ane) linker 
BM    1,8-bis-maleimidodiethyleneglycol linker 
CMV    cytomegalovirus 
c/p ratio   cation/plasmid (weight/weight) ratio 
Da    dalton  
DCM    dichloromethane 
DMEM   Dulbecco´s Modified Eagle´s Medium 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
DTT    dithiothreitol 
EGF    epidermal growth factor 
EGF-PEI epidermal growth factor covalently linked to PEI25K via a 
heterobifunctional 3.4 kDa PEG spacer; EGF/PEI ratio: 
1.2/1 
EGFR    epidermal growth factor receptor 
EtBr    ethidium bromide 
EtOAc   ethyl acetate 
FACS    fluorescence activated cell sorting 
FCS    fetal bovine serum 
GLDH    glutamate dehydogenase 
GPC  gel permeation chromatography 
HA    hexyl acrylate 
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HBG Hepes-buffered glucose (5 % (w/v) glucose, 20 mM 
Hepes, pH 7.4) 
0.5 HBS Hepes-buffered glucose and Hepes-buffered saline 1/1 
(v/v) 
HBS Hepes-buffered saline (5 % glucose (w/v), 150 mM NaCl, 
20 mM Hepes, pH 7.4); 
HD    1,6-hexanediol diacrylate linker 
Hepes   N-(2-hydroxyethyl)piperazine-N`-(2-ethane sulfonic acid) 
HPLC  high pressure liquid chromatography 
HT-OEI-HD1  OEI-HD polymer synthesized at 60 °C (= high 
temperature) and at molar input ratio of OEI/HD = 1/1  
IR    infrared spectroscopy 
kDa    kilodalton 
LT-OEI-HD  OEI-HD polymer synthesized at 22 °C (= low 
temperature) 
ME-A-MAL N-{3-[4-(4-{1-[bis-(2-methoxyethoxy)]methyl}phenyl)pi-
perazinyl]-3- oxopropyl} maleimide 
MFI    mean fluorescence intensity 
MK    2,2-bis(N-maleimidoethyloxy) propane linker 
Mn    m.w. by number 
Mp    m.w. at the peak maximum 
mPEG poly(ethylene glycol) monomethyl ether, average m.w. of 
5 kDa 
MTT    methylthiazoletetrazolium salt 
m.w.    molecular weight 
Mw    m.w. by weight 
N/P ratio   molar ratios of PEI nitrogen to DNA phosphate 
OEI800   oligoethylenimine with an average m. w. of 800 Da 
OEI-HD   HD-linked OEI800 
PBS    phosphate-buffered saline 
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pCMVLuc   plasmid encoding luciferase under control of the  
    CMV promoter/ enhancer 
PDI    polydispersity index 
pDNA    plasmid DNA 
PEG    poly(ethylene glycol) 
PEG5K   poly(ethylene glycol), average m.w. of 5 kDa 
PEG-A-MAL N-(3-{4-[4-(1-{bis[monomethoxy poly(ethylenoxy)]}methyl) 
phenyl]piperazinyl-]3-oxopropyl)maleimide 
PEG-A-PEI25K mPEG 5 kDa acetal conjugate with PEI25K 
PEG-MAL maleimide modified mPEG: methoxy poly(ethylene glycol) 
maleimido average m.w. of 5 kDa 
PEG-SH thiol modified mPEG: methoxy poly(ethylene glycol) thiol, 
average m.w. of 5 kDa  
PEG-S-PEI25K  mPEG of 5 kDa covalently and stably attached to PEI25K 
PEI    polyethylenimine 
PEI22K   linear PEI with an average m. w. of 22 kDa 
PEI1.8K/2K/10K/25K/50K branched PEI with an average m.w. of 2/10/25/50 kDa 
PEI-SH   thiolated PEI 
PLL    poly-(L-lysine), hydrobromide,  
PLL58K   PLL, average m.w. of 58 kDa 
RES    reticulo endothelial system 
RLU    relative light units 
RNA     riboxy nucleic acid 
r.t.    room temperature 
s.d.    standard deviation 
SEC    size exclusion chromatography 
SPDP    succinimidyl 3-(2-pyridyldithio)propionate 
THF    tetrahydrofuran 
TEA    triethylamine 
Tf    transferrin 
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Tf-PEI transferrin covalently linked to PEI25K via a heterobi-
functional 3.4 kDa PEG spacer; Tf/PEI ratio: 0.9/1  
TNBS    2,4,6-trinitrobenzenesulfonic acid  
v    volume 
Vp    elution volume at peak maximum  
w    weight 
λem     emission wavelength 
λex    exitation wavelength 
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6.2 Publications 
 
6.2.1 Original papers 
Knorr, V.; Allmendinger, L.; Walker, G.F.; Paintner, F.F.  and Wagner, E. (2007) 
An acetal based PEGylation reagent for pH-sensitive shielding of DNA polyplexes 
Bioconjugate Chem. 18 (4) 1218-1225 
 
Knorr, V.; Russ, V.; Allmendinger, L.; Ogris M. and Wagner, E. (2008) 
Acetal linked polyethylenimines for use as pH-sensitive gene carriers. 
Bioconjugate Chem., in press 
 
Manuscript in preparation 
Knorr, V.; Ogris M. and Wagner, E. 
An Acid Sensitive Ketal-based Polyethylene Glycol-Oligoethylenimine Copolymer 
Mediates Improved Transfection Efficiency at Reduced Toxicity. 
 
 
6.2.2 Poster presentation 
Knorr, V.; Allmendinger, L.; Walker, G.F.; Paintner, F.F.  and Wagner, E. (2007) 
pH-sensitive shielding of DNA polyplexes using a novel acetal-based PEGylation 
reagent. Poster 141, XVth Annual Congress of the European Society of Gene and 
Cell Therapy (ESGCT), October 27 – 30, 2007; Rotterdam. 
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